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ABSTRACT 
 
 Primary cancer is often treatable by radiation therapy, chemotherapy or surgery, 
but tumour invasion and metastasis still remains the most challenging problem to cancer 
patients, causing death through organ damage or treatment complications. Past 
researches have focused on these issues, but no major breakthroughs have been 
achieved to prevent tumour metastasis. Dysregulation in the expression of short non-
protein coding microRNAs (miRNAs) found contributes toward the initiation and 
progression of cancer through their capability to regulate multiple target genes. In this 
study, four pairs of high and low invasiveness sub-cell lines distinct in invasion and 
migration properties were established from their heterogeneous parental lung cancer cell 
line of A549, prostate cancer cell line of PC-3, breast cancer cell lines of MDA-MB-231 
and MCF7 using serial transwell invasion approach. To gain insight into the molecular 
mechanisms that contribute to cancer migration and invasion, miRNA microarray was 
conducted on the three paired-sub cell lines of A549, PC-3 and MCF7. Lists of 
significant differentially expressed miRNAs between the three paired cell lines were 
identified and a subset of miRNAs from A549 was validated by Real-Time PCR. 
Through pathway enrichment analysis, a hypothetical pathway model describing A549 
lung cancer metastasis was generated highlighting the network interaction of miRNAs 
and their gene targets. All these miRNAs act in concert in modulating three main 
pathways which were the non-canonical Wnt/planar cell polarity (PCP), transforming 
growth factor-β (TGF-β) and integrin signalling cascade to promote lung cancer 
migration and invasion. These results provide potential candidate metastatic markers for 
non-small cell lung cancer classification, prognosis and a possible therapeutic effect 
through targeting these miRNAs to control lung tumour invasion and metastasis. 
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ABSTRAK 
 
 Kanser primer selalunya boleh dirawat dengan terapi radiasi, kemoterapi atau 
pembedahan, namun invasif dan metastatik tumor tetap menjadi masalah yang paling 
mencabar untuk pesakit kanser, iaitu menyebabkan kematian melalui kerosakan organ 
atau komplikasi rawatan. Kajian-kajian terdahulu telah memberi tumpuan kepada isu-
isu ini, tetapi tiada penemuan utama telah dicapai bagi mencegah berlakunya metastatik 
tumor. Deregulasi dalam ekpresi microRNAs (miRNAs), RNA yang tidak mengekod 
protein telah menyumbang kepada permulaan dan perkembangan kanser melalui 
keupayaan mereka untuk mengawal pelbagai gen sasaran. Dalam kajian ini, empat 
pasang sub-sel yang berbeza dalam tinggi dan rendah ciri invasif dan migrasi telah 
dihasilkan daripada induk heterogenus sel kanser paru-paru A549, sel kanser prostat 
PC-3, sel kanser payudara MDA-MB-231 dan MCF7 dengan menggunakan kaedah 
“serial transwell invasion”. Bagi mendapatkan maklumat tentang mekanisma molekul 
yang menyumbang kepada migrasi dan invasif kanser, “miRNA microarray” telah 
dijalankan ke atas tiga pasang sub sel iaitu A549, PC-3 dan MCF7. Senarai miRNAs 
yang jelas menyatakan perbezaan miRNAs di antara pasang sel dari tiga jenis kanser 
tersebut telah dikenalpasti dan subset miRNAs dari A549 telah disahkan oleh “Real-
Time PCR”. Melalui analisis “enrichment pathway”, satu model laluan hipotesis yang 
menerangkan A549 metastatik kanser paru-paru dengan menunjukkan interaksi 
rangkaian miRNAs dan gen sasarannya telah dicadangkan. Semua miRNAs ini 
bertindak secara bersama dalam modulasi tiga laluan utama iaitu “non-canonical 
Wnt/planar cell polarity (PCP), transforming growth factor-β (TGF-β) and integrin 
signalling cascade” untuk menggalakkan migrasi dan invasif kanser paru-paru. 
Keputusan ini menunjukkan  petanda calon metastatik yang berpotensi untuk 
mengklasifikasikan “non-small” kanser paru-paru, prognosis dan kemungkinan nilai 
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terapeutik dengan mensasarkan miRNA untuk mengkawal invasif  tumor paru-paru dan 
berlakunya metastatik. 
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CHAPTER 1: INTRODUCTION 
 
 The three cancer types focused in this study are lung, breast and prostate as 
worldwide, lung cancer is the leading cause of cancer-related-deaths in males and 
second in females. Additionally breast cancer is the most common cancer type among 
females and prostate cancer is second among males (Kamangar et al., 2006; Jemal et 
al., 2011). Cancer metastasis is a complex, multiple-step processes that involved tumour 
cells to dislodge, spread and proliferate at distant sites from the primary tumour. The 
major cause of cancer related deaths in cancer patients is commonly attributed to its 
ability to metastasize to distant organs that causes organ damage or treatment 
complications. To date, the mechanism in which cancer metastasizes and relapses is still 
poorly understood (Bracken et al., 2009; Xia and Hu, 2010).   
 The process of migration, a hallmark of cell invasion, involves a complex 
interaction between proteins from transmembrane receptors to transcription factors, 
which triggers multiple-step cellular signalling events ranging from morphological 
changes to focal adhesion dynamics, actomyosin polymerization and contraction (Friedl 
and Bröcker, 2000). Among the signalling events commonly involved in cancer cell 
migration includes the integrin-FAK-Src signalling complex which regulates metastatic 
cells to loosen its extracellular matrix (ECM) adhesion and Rho-GTPases superfamily 
signalling proteins that play a significant role in the re-organization of the actin 
cytoskeleton to form filopodia, lamellipodia and stress fibers (Nobes and Hall, 1995; 
Hood and Cheresh, 2002). The epithelial to mesenchymal transition (EMT) is another 
essential in promoting tumour metastasis by causing the disruption of cell-cell 
adherence, matrix remodelling, increased motility and invasiveness. These process is  
regulated by signalling pathways of transforming growth factor-β (TGF-β), Wnt, 
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integrin, nuclear factor-κB (NF-κB), phosphatidylinositol 3-kinase (PI3K)/AKT and 
Notch pathway (Jing et al., 2011). 
 MicroRNAs (miRNAs) are short non-protein-coding RNAs of approximately 18 
to 24 nucleotides that post-transcriptionally regulate gene expression involved in 
various biological processes, including development, cell proliferation, differentiation 
and apoptosis (Hwang and Mendell, 2006). MiRNAs are particularly attractive 
candidates as upstream regulators of tumourigenesis and metastasis because they post-
transcriptionally regulate numerous target genes, thereby potentially enabling their 
intervention at multiple steps of the invasion-metastasis cascade (Bracken et al., 2009; 
Valastyan et al., 2009). Past studies have shown that dsyregulation in miRNA 
expression is associated with cancer which contributes toward tumour development 
including malignant transformation, angiogenesis and tumour metastasis (Du and 
Pertsemlidis, 2010). Recently, numerous studies have demonstrated that miRNAs such 
as miR-10b, miR-335, miR-126, miR-206, miR-373, miR-520c and miR-21 all play an 
important role in cancer cell invasion, migration and metastasis, where miR-10b acts as 
a pro-metastatic miRNA, while miR-335, miR-126 and miR-206 acts as anti-metastatic 
miRNAs (Ma et al., 2007; Tavazoie et al., 2008; Huang et al., 2008; Zhu et al., 2008). 
 Even though past studies have focused on issues revolving cancer metastasis, no 
major breakthroughs have been reported to prevent tumour metastasis. In order to 
elucidate the miRNAs required for the migration and invasion of metastatic cancers, 
comparative studies on the biological characteristics and genetic profiles between 
cancer cell variants possessing different degrees of migration and invasion properties 
were conducted. Malignant tumours are typically composed of heterogeneous cells with 
different phenotypic properties, with only a sub-population of cells possessing invasive 
and metastatic properties (Spremulli and Dexter, 1983; Gupta and Massagué, 2006). In 
this study, serial transwell invasion approach were employed to establish four pairs of 
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high and low invasiveness sub-cell lines that varies in invasion and migration properties 
from A549 lung cancer cell line, PC-3 prostate cancer cell line and MCF7 and MDA-
MB-231 breast cancer cell lines from each heterogeneous parental cancer cell lines. 
This was followed by miRNA microarray, quantitative Real-Time PCR validation and 
pathway enrichment analysis to highlight how the differentially expressed miRNA 
between sub-cell lines act in concert in modulating metastasis-related pathways for 
invasion and migration of cancer metastasis. 
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1.1 Research Question 
Since molecular mechanisms of common cancer types like lung, prostate and breast 
cancer metastasis still remain poorly understood, it is important to investigate on the 
miRNAs that contribute to the invasion and migration properties of these cancer types. 
 
1.2 Hypothesis 
The differentially expressed miRNAs between the high and low invasiveness sub-cell 
lines have potential in regulating migration and invasion for cancer metastasis. 
 
1.3 Study Objectives 
1)   To investigate the miRNA(s) involved in the invasive and migration properties 
of lung, prostate and breast cancer.  
2)  To establish high and low invasiveness sub-cell lines from each heterogeneous 
parental cell lines of A549, PC-3, MCF7 and MDA-MB-231 using serial 
transwell invasion approach. 
3)  To identify the differences in miRNAs expression profile between high and low 
invasiveness sub-cell lines using microRNA microarrays and validated using 
quantitative Real-Time PCR approach. 
4) To highlight the mechanism of differentially expressed miRNAs that act in 
concert in modulating metastasis-related pathways for the process of invasion 
and migration of cancer metastasis. 
5) To propose candidate cancer metastatic markers. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Cancer Overview 
Cancer is featured by uncontrolled cell proliferation and inappropriate survival 
of damaged cells or mutated cells resulting in tumour formation and able to gain ability 
to develop progressively and metastasize to other parts of the body through the blood 
and lymph (Yu et al., 2007; Tlsty and Coussens, 2006). Cancer can affect everybody 
and is the second highest killer after cardiovascular diseases in Malaysia (Chuah et al., 
2006). 
Cancer is the leading cause of death worldwide. Kamangar et al. (2006) reported 
that an estimated 11 million cancer incidences and 7 million cancer deaths occur 
worldwide, and about 25 million individuals were living with cancer (Kamangar et al., 
2006). A total of 21,773 cancer cases comprising of 9,974 males and 11,799 females 
were diagnosed among Malaysians in Peninsular Malaysia according to the National 
Cancer Registry (NCR) in 2006. Cancer is a rising health problem and can occur at all 
ages. Breast, colorectal, lung, cervix and nasopharynx cancer are the five most common 
cancer among the population in 2006 (Zainal et al., 2006). In this study, three cancer 
types of lung, prostate, breast cancer were focused and reviewed in this literature review.  
Lung cancer. Globally, lung cancer is the most commonly diagnosed cancer 
and is the leading cause of cancer-related-death, accounting for 1,179,074 cancer deaths 
per year (Kamangar et al., 2006). In year 2002, it was estimated that 1.35 million new 
cases of lung cancer occured in the world and 1.18 million deaths (Parkin et al., 2005). 
In Peninsular Malaysia, lung cancer is the second most frequent cancer type among 
males and the third most common cancer among populations. In year 2006, a total of 
2,048 new cases of lung cancer were registered with NCR in Peninsular Malaysia with 
1,445 being males and 603 females (Zainal et al., 2006).  
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Prostate cancer. In worldwide, prostate cancer is second most common cancer 
type in men and fifth most common cancer type among populations. It was estimated 
that 679,000 new prostate cancer cases was diagnosed and 221,000 deaths in the year 
2002 (Parkin et al., 2005). In Peninsular Malaysia, prostate cancer is the forth most 
common cancer among male where 735 new cases of prostate cancer were reported by 
NCR in year 2006 (Zainal et al., 2006).  
Breast cancer. Worldwide, breast cancer is the most common cancer type 
among females, with an estimated 1,152,161 new cases and 411,093 deaths per year 
(Kamangar et al., 2006). NCR reported that breast cancer is the most common 
diagnosed cancer type among women in Peninsular Malaysia. 3,525 female breast 
cancer cases was registered in the year 2006 and accounted for 16.5% of all cancer 
cases registered (Zainal et al., 2006).  
 
2.2 Cancer Metastasis Overview 
Metastasis is the most common cause of death for cancer patients and may occur 
through organ damage or treatment complications (Bracken et al., 2009).  
Lung Cancer. Lung cancer can be classified histologically into small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of 
lung cancer patients and two-third of these patients were diagnosed at late stages when 
the cancer has undergone local or distant metastasis, hence reducing the likelihood of 
curative surgery  (Berghmans, 2011). Lung cancer are commonly metastasize to brain, 
bone, and adrenals. Patient with untreated brain metastases have a median survival of 1 
month and this can be prolonged by another 1 month if treated with steroid and 3-8 
months with radiotherapy (Lagerwaard et al., 1999). The fact that metastasis accounted 
for high lung cancer mortality rates was further supported in a recent study indicating an 
overall poor prognosis in 313 patients with NSCLC and concurrent distant metastasis 
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with 45%, 48%, 12% 4% and 0% for 1-, 2-, 3-, 4- and 5- year survival rates respectively 
(Ma et al., 2006).   
Prostate Cancer.  Despite advancement of early prostate cancer detection via 
prostate specific antigen (PSA) based screening, about 20% of patient presented with 
metastatic at the time of diagnoses and metastasis is the major contributor of morbidity 
and mortality (Moul, 2000; Siddiqui et al., 2004). An autopsy study of 1,589 patients 
with prostate cancer done by Bubendorf et al. (2000) found 35% of patients detected 
with hematogeneous metastases where bone was most frequent organ detected with 
metastases, followed by liver, pleura and adrenals. Bone metastatic prostate is 
associated with various complications such as marrow failure, spinal cord compression 
and skeletal morbidity which later reduce the patient mobility and ultimately cause 
death (Saad et al., 2006). Prostate cancer treatment by blocking androgen receptors 
offers a temporary regression of advance prostate cancer, but it often progress into 
androgen independent metastatic stage in an approximately 18–36 months later (Baldi 
et al., 2003).  
Breast Cancer. Primary breast cancers are often treatable by surgery or 
radiotherapy, but relapse and metastatic spread can still occur at
 
distant sites that leads 
to fatal disease (Bracken et al., 2009). Breast cancer often first spreads through the 
lymphatics involving the regional lymph nodes such as the axillary nodes and 
commonly metastasized to lung, liver and bones for advance breast cancer. Regional 
lymph node status is one of the most important prognostic factors in breast cancer 
where the prognosis of breast cancer decrease as the number of tumour-positive lymph 
nodes increases (Cunnick et al., 2008). The prognosis of patients with liver metastasis is 
poor with only 16-25 months with chemotherapy (Pentheroudakis et al., 2006; Er et al., 
2008).  
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2.3 Cancer Metastasis Progression  
 Uncontrolled cell proliferation and angiogenesis are hallmarks of the initiation 
and early growth of primary cancers (Kalluri and Weinberg, 2009). 
 
 
Figure 2.1: Steps in the metastatic process (adapted from Ma and Weinberg, 2008). 
 
 Cancer metastasis is a complex sequential process by which primary tumour 
cells spread and grow at a secondary site. Cancer metastasis initially occurs with 
detachment of cancer cells from their neighbour cells. Cells then migrate and undergo 
local invasion through the basement membrane. Subsequently, metastatic cells 
intravasate to the blood circulation either directly or via the lymphatic system and 
survive in the circulatory system. Size constraints the cells attached to the vascular 
endothelium at a distant organ site (e.g. the lungs, bone or brain) or to the 
subendothelial basement membrane, tumour cells can then extravasate into the foreign 
tissue microenvironment. These cells may remain dormant or may proliferate and 
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stimulate blood vessel growth stimulation (angiogenesis) to allow micrometastases 
growth into macroscopic secondary tumours that are clinically detectable (Figure 2.1) 
(Ma and Weinberg, 2008; Bracken et al., 2009). 
 
2.3.1 Cancer Invasion and Epithelial-Mesenchymal Transition 
 Cancer cells changing its adhesive ability, gain migratory and invasive 
capabilities by involving dynamic reorganization of actin cytoskeleton through 
formation of membrane protrusions, leading to the mesenchymal phenotype (Yilmaz 
and Christofi, 2009).  
Cadherins, a transmembrane glycoprotein regulate the interactions between cells 
through extracellular domain, whilst its intracellular domain mediates signalling to the 
actin cytoskeleton (Halbleib and Nelson, 2006). Epithelial (E)-cadherin is expressed on 
epithelial cells and is important in mediating cell-cell and cell-matrix adhesion. While 
the expression of Neural (N)-cadherin on cancer cells form contact between cancer cell-
endothelial wall, this activates Src-kinases activity to promote transendothelial 
migration (Ramis-Conde et al., 2009).  
 
 
 
Figure 2.2: Overview of the role of EMT in tumour metastasis (adapted from Bracken 
et al., 2009). 
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Cell invasion is the initial step of cancer metastasis where tumour cells loss 
contact with the neighboring cells in primary tumour and migration through the ECM 
and basement membrane. EMT program has been proposed as the vital mechanism for 
epithelial cancer cells acquire invasion and migration of malignant phenotypes (Yilmaz 
and Christofi, 2009). Loss of cell-cell adherence by EMT program is characterized by 
reduced E-cadherin and up-regulated N-cadherin, which also known as “cadherin 
switch” (Araki et al., 2011). The sequential event of EMT can be triggered by many 
transcription factors such as snail1, zinc finger E-box binding homeobox (ZEB) and 
TWIST families that regulate actin cytoskeletal remodelling and ECM protein 
degradation by ECM-degrading proteases for examples matrix metalloproteinases 
(MMPs) and urokinase plasminogen activator (uPA). Actin cytoskeleton remodelling 
together with ECM degradation allow cell invasion into surrounding stroma and 
intravasation into the blood or lymphatic circulation. The cell is being carried away and 
extravasation to regional lymph nodes or distant organs. Later, a reversal event known 
as mesenchymal-epithelial transition (MET) with increased in expression of epithelial-
specific gene and repressed expression of mesenchymal-sepecific gene, thus leading to 
the formation of macroscopic metastases with epithelial characteristic at secondary site 
(Figure 2.2) (Bracken et al., 2009; Dykxhoorn et al., 2009; Baranwal and Alahari, 
2010). 
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2.3.2 Cancer Migration 
 Cell migration is vital during tumour invasion and metastasis progression 
(Stetler-Stevenson et al., 1993).  
 
 
Figure 2.3: Schematic diagram represented the major structures of the actin 
cytoskeleton in most of the migrating cell without a specific cell type (adapted from Le 
Clainche and Carlier, 2008). 
 
 In Figure 2.3, a schematic diagram represented the major structures (A) 
lamellipodium, (B) filopodium, (C) focal adhesion and (D) lamella of the actin 
cytoskeleton of a migrating cell (Le Clainche and Carlier, 2008). The migration 
mechanisms of tumour cells employ for spreading are similar to migration processes of 
normal cells such as embryonic morphogenesis, inflammatory immune responses, 
wound healing, and angiogenesis (Friedl and Bröcker, 2000).  
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Figure 2.4: A schematic diagram of cell migration (adapted from Ananthakrishnan and 
Ehrlincher, 2007). 
 
 In Figure 2.4, a combination of cellular events lead to dynamic actin 
cytoskeleton reorganization for a cell to migrate. First, cell polarized and elongated with 
extending protrusions in the direction of migration (also known as leading edge) in 
respond to migration-promoting agent. The spike-like filopodia or large and broad 
lamellipodia protrusions at leading edge are driven by actin polymerization and 
stabilized by adhering to extracellular matrix or adjacent cells via transmembrane 
receptors that linked to actin cytoskeleton. Subsequently, forward extension of 
lamellipodium by adhering to the surface of leading edge, while de-adhesion at the cell 
body and retraction of the rear end (also known as trailing edge) resulting in a net 
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translocation of the cell in the direction of the movement. In addition,
 
actin
 
filaments 
must be disassembled at the rear end, so that actin
 
monomers can be replenished for 
further polymerization at the
 
leading edge (Ridley et al., 2003; Pollard and Borisy, 
2003; Ananthakrishnan and Ehrlincher, 2007; Ding et al., 2008). 
 
2.3.3 Cancer Angiogenesis 
Tumour cell must arrest within the blood or lymphatic system through breaking 
local cell-cell adhesion and invasion into the surrounding stroma to metastasize. This 
process is further enhance by angiogenesis which allows tumour continued growth at 
primary site, thus providing access to the blood or lymphatic circulation. After 
intravasation into circulation, tumour cells must withstand the mechanical stress in the 
dynamic circulation and some able to arrest in capillary bed of distant organs by 
adhering to the endothelial cell surfaces or exposed subendothelial basement membrane 
and then extravasate into the tissue at the secondary site. These small metastasized cells 
are called micrometastases. This cells need to induce angiogenesis for vessels formation 
to get enough oxygen, nutrient and growth factor supply in order to survive and grow at 
secondary site (Bracken et al., 2009). 
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2.4  Cancer Metastasis-Related Signalling Pathways 
Multiple signalling molecules such as adhesion receptors, tyrosine kinases, 
cytoskeleton proteins, adapters and downstream signalling protein molecules interaction 
in signal transduction to regulate cancer migration and invasion (Bozzuto et al., 2010). 
Multiple signalling pathways including TGF-β, Wnt, integrin, NF-κB, PI3K/AKT, 
Notch and others were reported to regulate EMT in tumour microenvironment (Larue 
and Bellacosa, 2005; Jing et al., 2011). Recently, Scheel and colleagues demonstrated 
TGF-β, canonical and noncanonical Wnt signalling interaction to induce activation of 
the EMT program and thereafter function in an autocrine fashion to maintain cells in 
mesenchymal state (Scheel et al., 2011). Only the three signalling pathways of TGF-β, 
Wnt and integrin signalling pathways are discussed in the following literature review. 
 
2.4.1  TGF-β Signalling Pathway 
 TGF-β signalling pathway plays dual role in tumour progression. TGF-β exerts 
anti-proliferative effects on normal cells and early stage of tumour. As tumour develop 
or during late tumour stage, cancer cells start to promote cancer invasion and metastasis 
through regulating EMT, neoangiogenesis and escaping from immune surveillance 
(Jeon and Jen, 2010). Inhibition of TGF-β and TGF-β receptor has been shown to 
suppress metastasis, which indicates the involvement of TGF-β signalling pathway in 
cancer metastasis (Bandyopadhyay et al., 2006; Biswas et al., 2007).   
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Figure 2.5: Schematic diagram of canonical Smad-mediated TGF-β signalling pathway 
(adapted from Derynck and Zhang, 2003).  
 
 TGF-β ligands superfamily of TGF-β, activins, nodals, and bone morphogenetic 
proteins (BMP) play role in regulate tissue homeostasis and tumour proliferation, 
differentiation, and survival (Kato et al., 2002). In Figure 2.5, canonical Smad-mediated 
TGF-β signalling pathway is initiated when TGF-β ligand binding to TGF-β type II 
receptor (TGF-β-RII) leads to type I receptor (TGF-β-RI) employment and 
phosphorylation. This lead to activation of TGF-β-RII kinase domain in the cytoplasm 
which can then phosphorylates receptor-regulated Smad proteins (R-Smad), Smad2 and 
Smad3. Activated phosphorylated Smad2 and Smad3 form heteromeric complexes with 
Smad4, the common mediated Smad (co-Smad), then translocate into the nucleus to 
regulate a diverse array of genes transcription (Derynck and Zhang, 2003; Jeon and Jen, 
2010).  
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 Since TGF-β play an important role in regulate normal cellular homoeostasis, 
therefore a number of feedback mechanisms to maintain appropriate TGF-β signalling 
activation. TGF-β signalling is subjected to negative feedback by two inhibitory Smads 
(I-Smad), Smad6 and Smad7 which can inhibit Smad2/3 phosphorylation by interaction 
with TGF-β receptor (Hayashi et al., 1997; Imamura et al., 1997; Jeon and Jen, 2010). 
Smad7 also inhibits the Smad-mediated TGF-β signalling through the recruitment of 
Smad ubiquitin regulatory factors 1 (Smurf1) and 2 (Smurf2). Smurf1 and Smurf2 
induce ubiquitination and degradation of Smad2 and TGF-β family receptors (Ebisawa 
et al., 2001; Zhang et al., 2001; Jeon and Jen, 2010). In addition, TGF-β ligands also 
activate non-Smad mediated TGF-β signalling pathways including MAP kinase 
(MAPK) pathways, Rho-like GTPase signalling pathways and phosphatidylinositol-3-
kinase (PI3K)/AKT pathways (Zhang, 2009).  
 Levy and Hill (2006) reviewed that altered expression of TGF-β components 
such as ligands, TGF-β-RI, TGF-β-RII, Smad and antagonists of the Smad-mediated 
TGF-β signalling pathway were associated with various type of cancer tumourigenesis 
and metastasis (Levy and Hill, 2006). For example, inhibition of TGF-β signalling 
suppressing cancer metastasis was observed when Smad3 expression down-regulated or 
defective TGF-β-RI. This suggest an involvement of the canonical Smad-mediated 
TGF-β signalling pathway in tumour invasion and metastatic spreading (Tian et al., 
2003; Tian et al., 2004). Also, constitutive activation of TGF-β or TGF-β-RII were 
reported to promote EMT and cancer metastasis (Muraoka-Cook et al., 2004; Siegel et 
al., 2003).
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2.4.2 Wnt Signalling Pathway  
 Wnt signalling pathway plays important role in cell fate specification, cell 
migration, cell polarity, neural patterning and organogenesis during embryonic 
development. There are three intra-cellular signal transduction cascades can be activated 
by extracellular Wnt ligands: (i) canonical pathway and non-canonical pathways consist 
of (ii) planar cell polarity (PCP) and (iii) Wnt/Ca
2+
 pathway (Habas and Dawid, 2005; 
Komiya and Habas, 2008).  
 
2.4.2.1 Canonical Wnt Signalling Pathway  
 
Figure 2.6: A schematic representation of the canonical Wnt signalling pathway 
(adapted from Lai et al., 2009).  
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The canonical or Wnt/β-catenin dependent signalling pathway regulates cell fate 
and proliferation. β-catenin gets phosphorylated and targeted for ubiqitination and 
degradation by the proteosome when complexed with APC, axin and glycogen synthase 
kinase 3β (GSK3-β) in the absence of Wnt ligands binding (Figure 2.6A). In Figure 
2.6B, disheveled (Dvl for vertebrate/DSH for fly) activated upon Wnt ligand binding to 
transmembrane frizzled (Fz or Fzd) receptor and co-receptors lipoprotein receptor-
related protein 5 and 6 (LRP5/6). This prevents β-catenin from degraded by the 
destruction complex. β-catenin subsequently translocates into the nucleus and associates 
with T-cell factor/lymphocyte enhancer factors (Tcf/Lef) to form a transcriptional 
complex to activate downstream target genes expression (Komiya and Habas, 2008; Lai 
et al., 2009). Previous research found that involvement of Wnt canonical pathway in 
regulating proliferation and invasion of lung cancer cells when axin down-regulates 
TCF-4 transcription via β-catenin (Yang et al., 2010).  
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2.4.2.2 Non-Canonical Wnt Signalling Pathway  
 
Figure 2.7: A schematic representation of (A) the PCP and (B) Wnt/Ca
2+
 transduction 
cascade (adapted from Lai et al., 2009). 
 
Figure 2.7A, the PCP signalling pathway is transduced when non-canonical-Wnt 
ligand (Wnt-5a, Wnt-5b and Wnt-11) bind to Frizzled receptor (Fzd3 or Fzd6) leading 
to the recruitment of cytoplasmic scaffold protein of Dvl to the plasma membrane. 
Dishevelled-associated activator of morphogenesis 1 (Daam1) binds with Dvl and 
mediates activation of ras homolog gene family, member A (RhoA) which in turn 
activates Rho-associated protein kinase (ROCK). Daam1 also interact with Profilin to 
mediate actin polymerization in response to Wnt signal. In addition, Dvl mediates 
activation of Rac, which in turn activates c-Jun N-terminal kinases (JNK). Collectively,  
signal transduction cascade from ROCK, JNK and Profilin promote dynamic 
cytoskeleton alteration for cell polarization and migration (Komiya and Habas, 2008; 
Lai et al., 2009).  
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In Figure 2.7B, activation of the Wnt/Ca
2+
 transduction cascade when 
interaction of Wnt ligand with Fzd and co-receptor Knypek (Kny) or Ror2 increases 
intracellular calcium level and subsequently activates calcium/calmodulin-dependent 
protein kinase II (CaMKII) and protein kinase C (PKC). Wnt/Ca
2+ 
pathway has also 
been reported to play a crucial role in cell adhesion and mobility during gastrulation 
(Lai et al., 2009). 
 Numerous studies have shown that aberrant activation of the canonical and non-
canonical Wnt pathway promote cancer development and metastasis progression (Lee et 
al., 2008; Wang, 2009). For example, the non-canonical Wnt ligand, Wnt-5A, is 
involved in cancer progression and Wnt-5A over-expression has been found to be 
associated with aggressive tumour biology, increases cancer invasiveness and migration 
(Weeraratna et al., 2002; Kurayoshi et al., 2006; Pukrop and Binder, 2008).  
 
2.4.3  Integrin-FAK-Src Signalling Transduction 
 A complex interaction between extracellular matrix, transmembrane receptors, 
kinases, adapter proteins and other downstream signalling molecules triggers cell 
morphological changes to regulate cell migration (Friedl and Brocker, 2000). Integrin- 
focal adhesion kinase (FAK)-Src signalling transduction plays a role in regulating 
cancer metastatic cells by loosen cell-ECM adhesion and promoting cell invasion and 
migration (Hood and Cheresh, 2002). 
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Figure 2.8: An illustration of the integrin-FAK-Src signal transduction cascade in 
regulating actin cytoskeletal reorganization and focal adhesion complex for cell 
migration and cell elongation (adapted from Schneider et al., 2008). 
 
 Integrin function in tethering cell to the ECM, but activation of integrin induces 
recruitment of FAK and Src protein tyrosine kinase to trigger integrin-FAK-Src 
intracellular transduction cascades via multiple downstream proteins including the Rho 
GTPases superfamily proteins (such as Cdc42, Rac and RhoA) that play a significant 
role in the reorganization of the actin cytoskeleton to acquire a migratory and invasive 
phenotype (Figure 2.8) (Hood and Cheresh, 2002; Schneider et al., 2008). During cell 
movement, Cdc42 mediates formation of long, thin, actin-containing extensions called 
filopodia; Rac mediates formation of curtain-like extensions called lamellipodia and 
ruffles; whereas RhoA activation regulates formation of stress fibers (also known as 
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acto-myosin filaments) and focal adhesion of cells to induce retraction of the trailing 
edge (Nobes and Hall, 1995). 
 
 
Figure 2.9: Schematic representation of the formation of lamellipodia and filopodia 
(adapted from Heasman and Ridley, 2008).  
 
 
 
 23 
 In Figure 2.9A, a network of branched actin filaments formation with new actin 
filaments extended from the sides of existing filaments at the leading edge of the cell. 
During lamellipodium formation, Rac signal transduction activates downstream 
WAVE-Arp2/3 [(Wiskott–Aldrich syndrome protein (WASP)-family verprolin-
homologous protein)-(actin-related protein-2/3)] complex machinery that lead to actin 
polymerization. The possibly involvement of mDia2 (formin mammalian diaphanous-
2), which nucleates unbranched actin filaments in actin polymerization process. 
Extension of actin filaments were terminated when capping proteins bind to the barbed 
ends.  The lamella is located behind the lamellipodium which has longer and less 
branched actin filaments. Filopodia are thin fingerlike protrusions with non-branched 
parallel of actin filaments that are bundled together beyond the leading edge of 
lamellipodia of migratory cells. Filopodia were proposed to have possible function as 
sensory antenna toward environment or cell-cell contacts establishment (Heasman and 
Ridley, 2008).  
 In Figure 2.9B, Cdc42 bind to WASP, the related Neural (N)-WASP, or through 
the insulin-receptor substrate p53 (IRSp53) tyrosine kinase with Arp2/3 complex to 
induce branched actin filaments polymerization. Rac activates Arp2/3 complex through 
the WAVE complex. The contribution of these to filopodium protrusion is unknown. 
MDia2 activation by Cdc42 and Rac also trigger actin polymerization. In addition, the 
activation of Paks (p21-activated kinases), Pak1-3, the family of Ser/Thr protein kinases 
are one of the important downstream effectors of Rac and Cdc42. Paks then 
transphosphorylates
 
and activates downstream LIM kinase (LIMK), which 
phosphorylates and inhibits cofilin, thus regulating actin-filament turnover (Heasman 
and Ridley, 2008). 
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 Integrin signalling transduction cascade has been implicated in cancers and 
metastasis progression. A study done by Mizejewski (1999) showed a signature 
expression of integrins in malignant tumours compared with pre-neoplastic tumours. 
Strong expression of integrin αvβ3 were reported in high metastatic human melanoma 
cells and ectopic expression of integrin β3 subunit increases metastatic potential of 
melanoma cell line, this suggested that integrin play a role in invasive and metastatic 
cancer properties (Gehlsen et al., 1992; Filardo et al., 1995). Also, increase evidences 
of Rho GTPases family influence a variety of processes in cancer, including cell 
transformation, survival, invasion, metastasis, and angiogenesis (Espina et al., 2008). 
Furthermore, Fak, the downstream signalling molecule of integrin signalling is 
associated with cancer metastasis where high Fak expression was observed in metastatic 
cancer (Cance et al., 2000). 
 
2.5  MicroRNA (miRNA) 
Cancer is a complex genetic disease involving structural and expression 
abnormalities of genes with the accumulation of genomic alterations that activate 
oncogenes and inactivate tumour suppressors. A large number of cancer susceptibility 
genes have been identified in a variety of cancers in the past four decades. The 
discovery of genes that produce non-protein coding RNA transcript, known as 
microRNAs (miRNAs). Involvement of miRNAs in cancer pathogenesis have increased 
the genomic complexity of cancer cells in the past few years which might give a better 
understanding of tumourigenesis (Calin and Carlo, 2006; Yu et al., 2007).  
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2.5.1 MicroRNA Biogenesis  
 
Figure 2.10: Biogenesis and function of miRNAs (adadped from Sassen et al., 2008). 
 
MiRNAs are short non-protein-coding RNAs of 20-22 nucleotides that post-
transcriptionally regulate gene expression. Primary miRNAs (pri-miRNA) are long 
transcripts with hundred to thousand of nucleotides transcribed by RNA polymerase II 
before capping and polyadenylation. In Figure 2.10, pri-miRNA, which contains one or 
more stem-loop structures of about 60 to 100 nucleotides, are then excised by type III 
ribonuclease (Drosha) into precursor miRNA (pre-miRNA) in the nucleus. Pre-miRNA 
is exported into the cytoplasm and subsequently cleaved by the ribonuclease Dicer to 
generate a short RNA duplex (miRNA: miRNA*). The single stranded mature miRNA 
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(also known as guided strand) regulate gene expression in a sequence-specific fashion 
by incorporating it into an RNA-inducing silencing complex (RISC), while the 
miRNA* (also known as passenger strand or complementary strand) is generally 
degraded immediately. This mature miRNA binds to the 3’ untranslated region (3’ 
UTR) of target messenger RNAs (mRNAs) through imperfect complementarity with the 
seed sequence. Seed sequence is the bases 2 to 8 at the 5’ end of the mature miRNA, 
which defines miRNA families and is important for proper target recognition. The 
binding of miRNA to the 3’ UTR of mRNA causes inhibition of mRNA translation and 
impairs the stability of the mRNA, leading to a reduction in protein expression levels 
(Calin and Croce, 2006; Sassen et al., 2008; Nicoloso et al., 2009). 
Computational target prediction algorithms have been developed to identify 
putative mRNA targets based on the seed sequence of miRNA to search for 
complementary sequences in the 3’-UTRs of known genes that exhibit conservation 
across species. Due to the imperfect base pairing by miRNA, each miRNA is estimated 
to potentially target up to 200 mRNA targets and estimated to regulate up to one third of 
the human protein coding gene expression and potential regulators of many signalling 
pathways (Lewis et al., 2005; Yu et al., 2007; Heneghan et al., 2009).  
   
2.6  MiRNAs and Cancer 
MiRNAs have been shown to be involved in diverse biological processes, 
including development, cell proliferation, differentiation and apoptosis by 
simultaneously controlling the expression levels of hundreds of genes (Wu et al., 2007). 
Emerging data indicate that dysregulation of miRNAs were associated with certain 
types of cancer and also alteration in miRNA expression is likely to contribute to the 
initiation and progression of human cancer (Gregory and Shiekhattar, 2005; Sassen et 
al., 2008).  
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MiRNAs can affect tumourigenesis due to their ability to suppress target gene 
expression through base-pairing interactions with their target mRNAs. Some miRNAs 
can function as oncogenes. When a gene encoding a miRNA that targets one or more 
tumour suppressor genes is over-expressed, genomic amplification, or loses epigenetic 
silencing, tumourigenesis will be enhanced. By contrast, a miRNA act as a tumour 
suppressor when the situation above is the same except that the target of miRNA is an 
oncogene. The deletion in gene copy number or epigenetic silencing of a miRNA that 
functions to suppress the expression of oncogene(s) might allow the target mRNA and 
protein expression to increase and gain oncogenic potency. Mutations at the seed 
sequence of the mature miRNA could reduce or eliminate binding to key targets or even 
severely change its specificity for binding to the right targets, thereby altering the 
balance of genes and proteins expression for normal biological processes and thus lead 
to tumourigenesis (Venture and Jacks, 2009). 
The abnormal expression levels of miRNAs in tumours have important 
pathogenetic consequences. MiRNAs that are over-expressed in tumours generally 
function as oncogenes by exerting pro-oncogenesis effects by inhibiting key tumour 
suppressors. For example, the miR-17-92 cluster, located at the genomic regions 
amplified in lymphomas, promotes tumourigenesis by inhibiting tumour suppressor 
E2F1 transcription factor. Also, miR-21 represses the tumour suppressor phosphatase 
and tensin homolog (PTEN) in hepatocellular carcinoma (HCC). MiRNAs deleted or 
down-regulated in tumours generally participate in oncogene over-expression. For 
example, the down-regulation of tumour suppressor miRNA, let-7 in lung cancer allow 
the over-expression of its target oncogenes such as KRAS, NRAS, high mobility group 
A2 (HMGA2) and MYC. Besides that, down-regulation of tumour suppressor genes of 
miR-15a–miR-16-1 cluster allow for the expression of B-cell CLL/lymphoma 2 
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(BCL2), an anti-apoptotic gene in B-cell chronic lymphocytic leukaemia (B-CLL) 
(Bracken et al., 2009; Nicoloso et al., 2009). 
MiRNA-expression profiling of human tumours provide a remarkable ability to 
distinguish tumour from normal tissue. This revealed a list of specific miRNA 
signatures associated with cancer diagnosis, staging, progression, metastasis, prognosis, 
survival rates and response to treatment. This may be of particular benefit for the 
diagnosis of cancers of histologically uncertain origin, where miRNA profiling may be 
of greater significance than mRNA profiling in the ability to diagnose the origin (Calin 
and Croce, 2006; Bracken et al., 2009). 
 
2.7 MiRNAs and Cancer Metastasis 
MiRNA was first recognized to play a role in human cancer in 2006. Following 
that, many studies have indicated that miRNA target multiple proteins that are essential 
for various signalling pathways  (Nicoloso et al., 2009). The ability of miRNAs post-
transcriptionally regulate various target genes enabling them interference at multiple 
steps of the invasion metastasis cascade. Therefore, miRNAs are particularly attractive 
candidates as upstream regulators of tumourigenesis and metastasis (Bracken et al. 
2009).  
Multiple miRNAs that are associated with metastasis and poor prognosis have 
been identified through miRNA profiling or functional studies. MiRNA regulates 
metastasis-associated genes that are vital in tumour invasion and metastasis through 
inhibitory process. Metastasis-associated miRNAs is grouped into pro-metastatic 
miRNA and anti-metastatic miRNA. A pro-metastatic miRNA targets and inhibits 
metastasis-suppressor genes, thus promoting cancer metastasis, whilst an anti-metastatic 
miRNA suppresses metastasis-promoting genes, hence demoteing cancer metastasis 
(Zhang et al., 2010). 
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2.7.1 Pro-Metastatic MiRNAs 
miR-10b. miR-10b was first discovered by Ma and colleagues (2007) as a pro-
metastatic miRNA. miR-10b was highly expressed in metastatic cells and potentially 
regulates cell migration and invasion of breast tumour. miR-10b was ectopically over-
expressed in non-invasive breast cells to explore the ability to drive metastasis. The 
result showed that extopic expression of miR-10b allowed non-invasive cells to gain 
invasion and metastatic properties in vitro and in vivo without affecting the viability or 
proliferation properties.  
Homeobox 10 (HOXD10), a transcription factor that is associated with cell 
migration and ECM remodeling was validated as a target of miR-10b. Down-regulation 
of HOXD10, by over-expression of miR-10b, led to de-repression of the downstream 
HOXD10 target RhoC, a pro-metastatic Rho-family GTPase. Thereby, through 
repression of HOXD10, miR-10b promotes RhoC expression and, hence, promotes 
metastasis. This is shown clinically in metastatic free patient with reduced expression of 
miR-10b, whilst increased expression is noted in 50% of patient with metastasis. These 
findings represent the first functional evidence that over-expression of a miRNA can 
contribute to tumour invasion and metastasis (Ma  et al., 2007). 
Later in 2010, Ma and colleagues published another paper that demonstrated 
tumour-bearing mice treated systemically with miR-10b antagomirs able to suppress 
breast cancer metastasis. Silencing of miR-10b with antagomirs significantly reduced 
miR-10b levels and increased the levels of HOXD10 in both in vitro and in vivo. 
Administration of miR-10b antagomirs to mice bearing highly metastatic cells do no 
have effect on the growth of the primary tumour but significantly suppresses lung 
metastasis. As a result, miR-10b antagomir appears to be a potential candidate for the 
development of new anti-metastasis agents as it is well tolerated by normal animals. 
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miR-373 and miR-520c. Huang and colleagues (2008) revealed both miR-373 
and miR-520c did not affect cell proliferation, but promoted MCF7 cells migration in 
vitro. By introducing MCF7 cells with miR-373 or over-expressing miR-520c in nude 
mice, these miRNAs were found to increase in vivo metastasis with formation of 
secondary tumours in bone, brain and lung, whilst the parental MCF7 cells failed to 
form metastases. CD44 adhesion molecule was found to be the common target of miR-
373 and miR-520c (Huang et al., 2008; Yang et al., 2009). Moreover, miR-373 as a 
metastasis-associated miRNA was further supported by clinical breast cancer data 
where miR-373 is over-expressed and inversely correlated with CD44 expression in 
breast carcinomas, especially in those with lymph node metastasis (Huang et al., 2008).  
In another lab, miR-373 was identified as an oncogene in testicular germ-cell tumours 
that promoted cellular proliferation and tumourigenesis but not metastasis (Voorhoeve 
et al., 2006; Zhang et al., 2010). 
miR-21. Multiple independent studies have indicated a direct link to the over-
expression of miR-21 with an increase in cancer metastasis by down-regulating several 
metastasis suppressor gene expression that encoded programmed cell death 4 (PDCD4), 
maspin, phosphate and tensin homolog (PTEN), tropomyosin 1 and tissue inhibitor of 
metalloprotease-3 (TIMP3). These genes act as suppressors in neoplastic 
transformation, cell motility and invasiveness (Meng et al., 2007; Asangani et al., 2008; 
Frankel et al., 2008; Gabriely et al., 2008; Lu et al., 2008; Zhu et al., 2008). In addition, 
Huang and colleagues (2009) reported that miR-21 is associated with up-regulation of 
human epidermal growth factor receptor 2 (HER2)/neu and is functionally involved in 
HER2/neu-induced breast cancer cell invasion. In addition, a significant correlation 
between the expression of miR-21 with advanced clinical stage, metastasis and poor 
prognosis in tumours were observed (Krichevsky and Gabriely, 2009). 
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miR-182. Comparison between normal melanocytes and melanoma cell lines 
expression profiles revealed over-expressed miR-182 as a pro-metastatic miRNA in 
melanoma cell lines. Over-expression of miR-182 induces migration and metastasis of 
melanoma cells in vitro and in vivo by directly repressing microphthalmia-associated 
transcription factor-M (MITF) and forkhead box O3 (FOXO3). In contrast, down-
regulation of miR-182 suppress invasion and induce apoptosis, thus silencing miR-182 
could be a therapeutic strategy for melanoma (Segura et al., 2009; Baranwal and 
Alahari, 2010, Zhang et al., 2010). 
miR-9. miR-9 is a pro-metastatic miRNA that targets mRNA encoding E-
cadherin, a key metastasis-suppressing protein that plays a vital role in tumour 
migration and invasion. Animal model study showed that over-expression of miR-9 in 
non-metastatic breast tumour cells allowed the cells to gain ability to metastasize, whilst 
supression of miR-9 expression causes the highly maligant cells to lost its metastatic 
ability (Ma et al, 2010). Later, Zhu and colleagues (2011) demonstrated participation of 
miR-9 in regulating metastatic process of colorectal cancer (CRC) though promoting 
cell migration. Recently, miR-9 was identified to inhibit melanoma proliferation and 
metastasis through inhibition of NF-κB-Snail1 pathway by up-regulation of E-cadherin 
(Liu et al., 2012). 
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2.7.2 Anti-Metastatic MiRNAs 
miR-335, miR-126 and miR-206. Tavazoie et al. (2008) identified three lower 
expression miRNAs, miR-335, miR-126 and miR-206 in both metastatic breast cell 
lines and metastases. Restoration of these miRNAs expression in metastatic MDA-MB-
231 cells not only decreased cell migration and invasion in vitro but also significantly 
decreased the number of metastases in mouse model. SRY-box containing transcription 
factor (SOX4), tenascin C (TNC), receptor-type tyrosine protein phosphatase (PTPRN2) 
and c-Mer tyrosine kinase (MERTK) are the set of genes regulated by miR-335 and is 
associated with distal metastasis risk. Furthermore, patients with primary breast cancer 
expressing low levels of miR-335, miR-206 and miR-126 were associated with 
metastatic relapse (Bracken et al., 2009). Recently, the expression of miR-206 was 
inversely associated with invasion and metastatic capacities of lung cancer (Wang et al., 
2011). 
miR-146a/b. A reduction in MDA-MB-231 breast cancer cell line metastatic 
capacity was seen when expression of miR-146a and miR-146b suppressed NF-κB 
through repression of interleukin 1 receptor-associated kinase 1 (IRAK1) and tumor 
necrosis factor receptor-associated factor 6 (TRAF6) (Bhaumik et al., 2008). Hurst and 
coworkers (2009) showed that miR-146 expression regulated by breast cancer 
metastasis suppressor 1 (BRMS1)  inhibit breast cancer metastasis through NF-κB 
pathway. Ectopic expression of miR-146a or miR-146b in MDA-MB-231 inhibiting 
invasion and migration in vitro as well as lung metastasis in vivo  through suppression 
of epidermal growth factor receptor (EGFR) expression. 
miR-183. Wang and coworkers (2008) identified miR-183 as a negative 
regulator of lung cancer metastasis through screening on low and high metastatic lung 
cancer cell lines using miRNA array. Ectopic expression of miR-183 in highly 
metastatic cells could inhibit cell migration and invasion of lung cancer cells. Ezrin, a 
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well established gene that mediating cell migration and metastasis through controlling 
the actin cytoskeleton, cell adhesion and motility was confirmed as a target gene of 
miR-183 by luciferase reporter gene assay.  
 miR-205. Invasion of breast cancer and esophageal squamous cell carcinoma 
(ESCC) was modulated by miR-205. A significant lower expression of miR-205 in 
breast tumour compared to normal breast tissue were observed. In addition, miR-205 
has lower expression in breast cancer cell lines (MCF-7 and MDA-MB-231) compared 
with the non-malignant breast cell line, MCF-10A. This is supported by ectopic 
expression of miR-205 in breast cancer cell lines significantly suppresses cell 
proliferation, encourage independent growth, cell invasion and metastasis. They also 
demonstrated that miR-205 was able to block breast cancer in vivo metastasis to lung. 
Finally, western blotting combined with the luciferase reporter assays show that 
vascular endothelial growth factor A (VEGF-A) and ErbB3 are direct targets for miR-
205. Together, these results suggest that miR-205 act as an anti-metastatic miRNA in 
breast cancer (Wu et al., 2009; Wu and Mo, 2009).  
 
2.7.3 MiRNA and Epithelial-Mesenchymal Transition 
EMT is characterized by the conversion of non-motile epithelial cells via lossing  
cell adhesion, repression of E-cadherin expression, then acquisition of mesenchymal 
markers (such as vimentin, fibronectin, and N-cadherin) into mesenchymal cells with 
increased cell motility and invasiveness (Ma and Weinberg, 2008; Ouyang et al., 2010). 
During tumour progression and differentiation, cancer cells undergo EMT to enhance 
tumour invasion and metastasis and resulting in poor clinical outcome. Multiple 
miRNAs that regulates EMT were indentified in recent years (Nicoloso et al., 2009). 
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miR-200 family and miR-205. The miR-200 family (miR-200a, miR-200b, 
miR-200c, miR-141 and miR-429) and miR-205 are key regulators of E-cadherin and 
were down-regulated in the cancer cells that undergo EMT. In year 2008, scientist from 
different labs have shown that miR-200 family suppress EMT and cancer cell migration 
and invasion by direct repressing mRNA encoding E-cadherin transcriptional repressors 
of ZEB1 and ZEB2. MET occurred in cells that had previously undergone EMT when 
ectopic expression of the miR-200 family or miR-205, followed by down-regulation of 
ZEB1 and ZEB2 and up-regulation of E-cadherin (Gregory et al., 2008; Korpal et al., 
2008; Park et al., 2008). Gregory and coworkers (2008) showed that miR-200 family 
and miR-205 may be the downstream molecules of the TGF-β as the miR-200 family 
and miR-205 are markedly down-regulated in cells that undergo EMT in response to 
TGF-β. TGF-β is a very important mediator of EMT in late-stage carcinomas to 
promote invasion and metastasis. ZEBs is able to form a reciprocal-negative feedback 
loop between the miR-200 family and ZEB1/ZEB2 by repressing the transcription of 
miR-200. Such a feedback loop enables maintenance of a stable bi-phasic state whilst 
retaining the ability to switch between states after an appropriate stimulus such as TGF-
β (Bracken et al., 2009). These miRNAs were proposed to as a control switch between 
EMT and MET in normal tissue homeostasis (Zhang et al., 2010; Baranwal and Alahari, 
2009).  
miR-101. miR-101 is another important regulator in EMT by directly targeting 
mRNA encoding enhancer of zeste homolog 2 (Ezh2). Ezh2, a histone methyl 
transferase, is an epigenetic regulator contributing to the epigenetic silencing of E-
cadherin and other target genes to control tumour cell proliferation, invasiveness and 
metastatic ability. Ectopic expression of miR-101 suppresses invasion capacity, while 
Ezh2 expression restoration rescues the invasiveness of PC-3 prostate cells. Also, miR-
101 differentially modulates prostate cancer cell proliferation (Cao et al., 2010).   
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2.7.4 MiRNAs Modulate Cancer Angiogenesis 
Angiogenesis is essential for tumours cells to intravasate and disseminate 
through the systemic circulation to distant site (Zhang et al., 2010). Recent studies 
suggested miRNAs play a key role in angiogenesis during tumour progression. Several 
miRNAs have been showed to have pro-angiogenesis and anti-angiogenesis properties.  
mir-17-92 cluster. Mir-17-92 cluster (including miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b and miR-92a) was found to play a role in tumour angiogenesis-
promoting activity. In RAS-expressing cells, these miRNAs that activated by MYC can 
enhance growth in tumour blood supply.  Connective tissue growth factor (CTGF) and 
adhesive glycoprotein thrombospondin 1 (Tsp1) are both anti-angiogenic genes that are 
targeted by the miR-17-92 cluster where down-regulation of both CTGF and Tsp1 were 
reported to promote neovascularization. Restoration of Tsp1 and CTGF expression were 
observed after knockdown of miR-17-92 (Dews et al., 2006). Otsuka et al. (2008) 
demonstrated miR-17-5p inhibits proliferation and motility of endothelial cell by 
targeting and down-regulating the expression of anti-angiogenic factor of TIMP-1 in 
mouse model.  
 miR-126. miR-126 is an endothelial-specific miRNA which is highly expressed 
in human endothelial cells. miR-126 reported to play an essential role in the regulation 
of various aspects of endothelial cell biology in vitro, including cell migration, 
organization of the cytoskeleton, and capillary network stability (Wu et al., 2009). 
Knockout of miR-126 in zebrafish and mice showed loss of vascular integrity and 
neoangiogenesis. The pro-angiogenic activity of miR-126 enhance VEGF levels and 
endothelial cell proliferation by directly suppressing negative regulators of the VEGF 
pathway such as sprouty-related protein 1 (SPRED1) and phosphoinositol-3 kinase 
regulatory subunits 2 (PIK3R2) (Fish et al., 2008; Wang et al., 2009).  
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 miR-296. Würdinger et al. (2008) reported up-regulation of miR-296 in primary 
tumour endothelial cells as compared to normal brain endothelial cells. Inhibition of 
miR-296 suppresses angiogenesis in animal model. The hepatocyte growth factor-
regulated tyrosine kinase substrate (HGS) is a direct target of miR-296 that inhibits 
angiogenesis by mediating degradation of pro-angiogenesis receptors of VEGF receptor 
2 (VEGFR2) and platelet-derived growth factor (PDGF) receptor β (PDGFR-β). Thus, 
elevated expression of miR-296 leading to decrease of HGS followed by indirectly up-
regulation of the expression of receptor for pro-angiogenic ligands VEGF and PDGF in 
tumour associated endothelial cells to promote angiogenesis. 
 miR-211 and miR-222. Both miR-211 and miR-222 are highly expressed in 
endothelial cells that exerts anti-angiogenic effects. Transfection of endothelial cells 
with miR-221 and miR-222 can reduce endothelial cell migration, proliferation, and 
angiogenesis in vitro by post-transcriptionally inhibiting the expression of protein c-Kit, 
the receptor for stem cell factor (SCF) (Poliseno et al., 2006). Also, another research 
showed miR-221/222 might be involved in vasculogenesis where over-expression of 
both miRNAs indirectly regulate the expression of the endothelial nitric oxide synthase 
(eNOS) in Dicer-knockdown endothelial cells (Suárez et al., 2007).  
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CHAPTER 3: METHODOLOGY 
 
3.1 Cancer Cell Cultures 
3.1.1 Cultivation of Cell Lines  
A549 (human lung adenocarcinoma epithelial cell line) and MCF7 (human 
breast adenocarcinoma cell line) were obtained from Cancer Research Initiatives 
Foundation (CARIF), while MDA-MB-231 (human breast adenocarcinoma cells) and 
PC-3 (human prostate cancer cell line) were purchased from American Type Culture 
Collection (ATCC). 
A549, PC-3 and MCF7 were maintained in Roswell Park Memorial Institute 
1640 (RPMI 1640) (Thermo Scientific Hyclone, USA) culture media whilst MDA-MB-
231 was cultivated in Dulbeco’s Modified Eagle Medium (DMEM) (Thermo Scientific 
Hyclone, USA) culture media. Culture media was supplemented with 10.0 % (v/v) fetal 
bovine serum (FBS) (JR Scientific Inc, USA) to provide complete nutrient for cell 
growth. All cell lines were adherent cells that were cultured on a 25.0 cm
2
 T-25 culture 
flask (Nunc, Denmark) and incubated at 37ºC in a carbon dioxide (CO2) incubator 
(Memmert, Germany) with 95.0 % humidified atmosphere. Culture media have buffer 
system that contained appropriate amount of bicarbonate where 5.0 % atmosphere CO2 
levels help maintain culture media in a balanced controlled pH (7.0 to 7.6).  
Subculturing of cells was performed when monolayer cell culture attained 70-
90% confluency to maintain healthy cell growth. First, the spent media was discarded 
and washed with 5.0 ml 1X Phosphate Buffered Saline (PBS). Then, 1.0 ml of 0.1 % 
(v/v) Trypsin-0.53 mM EDTA was added and incubated in 37ºC for 10 min to detach 
the cells. 2.0 ml of culture media with 10.0 % (v/v) FBS was added to inactivate trypsin 
activity. 0.5 ml of the cell suspension was mixed with 4.5 ml of fresh culture media and 
transferred all into a new T-25 culture flask.  
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3.1.2 Preparation of Frozen Stocks 
 Cancer cells were plated on a T-25 culture flask and grown to 70% confluency. 
Once desired confluency was obtained, the spent culture medium on the plate was 
discarded, cells were washed with 1X PBS and 1.0 ml of 0.1% (v/v) Trypsin-0.53 mM 
EDTA was added to detach cells from the culture flask for 10 min. 2.0 ml of culture 
media supplemented with 10.0 % (v/v) FBS were added to inactivate trypsin activity. 
Cell suspension was pipetted into 15.0 ml tubes and centrifuged at 125 x g for 10 min 
using Centrifuge 5702 (Eppendorf, USA). Supernatant was discarded and cell pellet 
was re-suspended with cyroprotectant medium supplemented with 20.0 % (v/v) FBS, 
10.0 % (v/v) Dimethyl sulfoxide (DMSO) (Merck, Germany). Several stocks of 1.0 ml 
aliquots of cells were prepared in 2.0 ml cryovials, frozen gradually at -4ºC, -20ºC for 3 
h each and finally long term stored in liquid nitrogen at -196ºC. 
 
3.1.3 Thawing of Cryopreserved Cells 
 Cyropreserved cells were removed from liquid nitrogen and the vials were 
thawed by gently agitation in 37ºC water bath for 2 min. Each 1.0 ml of thawed cell 
suspension was then diluted with 9 ml of culture medium supplemented with 10.0 % 
(v/v) FBS and centrifuged at 125 x g for 7 min. Cell pellet was re-suspended with 
culture medium supplemented with 10.0 % (v/v) FBS. 
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3.1.4 Trypan Blue Dye Exclusion Assay 
 Trypan blue dye exclusion assay was used to determine the number of viable 
cell in a cell suspension. Cells were detached, centrifuged and re-suspended in culture 
media. 1:1 dilution was prepared where 20.0 μl of cell suspension was suspended with 
20.0 μl of 0.04 % (w/v) trypan blue dye (Merck, Germany) and mixed thoroughly. Cell 
mixture was loaded into the counting chamber of a haemacytometer and only viable 
cells that excluded stain lying within the grid line of 1 mm
2
 area were counted under 
Nikon ECLIPSE TS-100 inverted microscope (Nikon, Japan).  
 
Cell concentration (cells/ml) = n x 10
4
 x (dilution factor = 2) 
      Number of squares counted              (Equation 3.1) 
 
where,  n = total viable cells counted 
 
3.2 Serial Selection of High and Low Invasiveness Sub-Cell Lines  
Selection of highly invasive subpopulations from parental cell lines A549, 
MCF7, MDA-MB-231 and PC-3 was performed using 24-well transparent PET 
membrane 8.0 μm pore size inserts (BD Biosciences, USA). Transwell inserts were 
coated with 100.0 ul of 1.5 mg/ml Matrigel (BD Biosciences, USA). Cells were re-
suspended in culture media  supplemented with 10.0 % (v/v) FBS and seeded into the 
upper chamber, while the bottom chamber was filled with media supplemented with 
20.0 % (v/v) FBS as chemo-attractant to create a chemotactic gradient for cell invasion 
to the bottom well. Following incubation for 48 h at 37ºC, invasive cells invaded 
through the Matrigel and attached on the bottom of the membrane, while remaining 
non-invasive cells on the top membrane were harvested aseptically and cultured for 
enough cells to subjected sequential selection. Selection for low invasiveness cells and 
high invasiveness cells was continued up to the seventh generation. Those low 
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invasiveness cancer cells which failed to invade all 7 rounds of selection were 
designated as A549-NI7, MCF7-NI7, MDA-MB-231-NI7 and PC-3-NI7 sub-cell lines, 
whilst those high invasiveness cancer cells successfully invaded through all 7 rounds 
were designated as A549-I7, MCF7-I7, MDA-MB-231-I7 and PC-3-I7 sub-cell lines 
(Figure 3.1). 
 
 
Figure 3.1: An illustration of high and low invasiveness sub-cell line selection using 
serial transwell invasion assay.  
 
3.3  Transwell Invasion Assay 
Cell invasiveness capacity of selected cancer sub-cell lines was examined using 
Transwell Invasion assay by measuring the number of cells transmigrating through a 
layer of extracellular matrix, Matrigel. 24-well transparent PET membrane 8.0 μm pore 
size inserts were coated with 70.0 ul of 1.5 mg/ml Matrigel (BD Biosciences, USA). 
70% confluent cells were starved with serum free media and harvested at 24 h. A 
density of 1.0 x 10
5 cells were resupsended with 500.0 μl of serum free media (Thermo 
Scientific Hyclone, USA) were added to the upper insert, whilst media with 20.0 % 
(v/v) FBS were added at a lower insert as a chemoattractant. The cells were incubated 
chemoattractant  8 μm pore PET membrane 
coated with Matrigel 
48 Hrs 
Invaded cells 
Harvest and 
repeat up to 7th 
round of selection 
Harvest 
and 
expand 
+ 
 low invasiveness cells 
 high invasiveness cells 
Non- invaded cells 
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for 22 h at 37 ºC. Cells in the upper insert were removed by swiping with cotton swabs 
and those invading cells on the underside of the membrane were fixed in 100.0 % 
ethanol for 2 min, followed by staining with 1.0 % (w/v) methylene blue (Sigma, USA) 
for 20 min. Number of invaded cells in eight random fields of each transwell invasion 
membrane insert areas were counted under Nikon ECLIPSE TS-100 inverted 
microscope (Nikon, Japan) at 200X magnification.  
  
3.4 Wound Healing Assay 
Wound healing assay was performed to examine the cell migration capacity. The 
selected low and high invasiveness sub-cell lines were grown to 100.0 % confluence in 
6-well plates and treated with Mitomycin C (Merck, Germany) at 1.0 μg/ml for 2 h to 
halt cell proliferation. A wound was created by dragging a 200.0 μl pipette tip through 
the cell monolayer. Cells were washed with 1x PBS to remove cell debris. The cells 
were then cultured in serum free media and allowed cells to migrate for 23 to 28 h. The 
wound healing activity of the same area was captured under an inverted microscope 
(Nikon, Japan) at 100X magnification at 0 h and 23 to 28 h. The open wound area of 
each image was assessed by TScratch software version 7.8 (Gebäck et al., 2009). The 
cell migrated or wound healing rate was calculated using the formulas shown in 
equations 3.2 and 3.3. 
 
Wound healing (%) = (open image area at start - open image area at end) x 100 
    open image area at start 
      (Equation 3.2) 
Fold change = % of wound healing of high invasive sub-cell line 
  % of wound healing of low invasive sub-cell line 
(Equation 3.3) 
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3.5 Cell Proliferation Assay 
Cell proliferation rate of parental, high and low sub-cell lines were determined 
by plating 2 x 10
4
 viable cells in 6-well plates with complete media. Spent media were 
discarded and replenished with fresh complete culture media every 2 days to ensure 
optimum growing condition for cells. Total viable cell number was counted every 24 h 
for 7 days using trypan blue dye exclusion assay. Cells were harvested, stained with 
trypan blue (Sigma Aldrich, USA) and total viable cells number were counted using a 
haemacytometer. A line graph was plotted with total viable cell number against 
harvested day. 
 
Doubling time  =    ln 2      x  number of days    
 ln (ratio)               (Equation 3.4) 
 
where,  Ratio = Total viable cell number on harvest day       
   Total viable cell number seeded on day-0   
 
3.6 Total RNA Extraction 
 Total RNA including small RNA population was extracted from 70.0 % 
confluency cultured low and high invasiveness sub-cell lines of A549, MCF7 and PC-3 
using Qiagen miRNeasy mini kit (Qiagen, Germany) according to manufacturer’s 
instruction. First, cells (≤ 1 x107 cells) were harvested by centrifuging for 10 min using 
Centrifuge 5702 (Eppendorf, USA). The tube was flicked thoroughly to loosen the cell 
pellet. A total of 700.0 μl of QIAzol lysis (Qiagen, Germany) was added and vortexed 
to mix. Cell lysates were homogenized by QIAshredder homogenizers (Qiagen, 
Germany) at maximum centrifuge speed for 2 min. The homogenate lysates were placed 
on the benchtop at room temperature for 5 min to promote dissociation of nucleoprotein 
complexes. 140.0 μl of chloroform was added to each of the tube containing the 
homogenate lysate and securely capped to shake vigorously for 15 s. The homogenate 
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lysates were placed on the benchtop at room temperature for 2-3 min for phase 
separation, then the lysates were centrifuge for 15 min at 12,000 x g at 4 ºC to separate 
the sample into 3 phases: an upper, colorless, aqueous phase containing RNA; a white 
interphase containing DNA; and a lower, red, organic phase containing protein. The 
solution at upper aqueous phase containing RNA was transferred to a new RNase free 
collection tube. 1.5 volumes of 100.0 % ethanol was added and mixed thoroughly by 
pipetting. 700.0 μl of the sample was pipetted into an RNeasy Mini spin column 
(Qiagen, Germany) in a 2.0 ml collection tube and centrifuge at 8,000 x g for 15 s at 
room temperature. The flow-through was discarded. 500.0 μl Buffer RPE (Qiagen, 
Germany) was pipetted onto the RNeasy Mini spin column and centrifuged for 15 s at 
8,000 x g to wash the column. The flow-through was discarded. Another 500.0 μl of 
Buffer RPE was added to the RNeasy Mini spin column and was centrifuged for 2 min 
at 8,000 x g to final dry the RNeasy Mini spin column membrane. The RNeasy Mini 
spin column was transferred to a new RNease free 1.5 ml collection tube and 40.0 μl of 
RNase-free water was added directly onto the RNeasy Mini spin column membrane and 
centrifuged for 1 min at 8,000 x g for RNA elution. RNA samples were then stored at -
30 ºC until further experiments. 
 
3.7 RNA Quality Control 
3.7.1 Nanodrop Spectrophotometry 
The purity and quantity of isolated RNA samples were assessed using Nanodrop 
2000 spectrophotometer (Thermo Scientifc, USA). First, Nucleic Acid application 
module was selected and the “RNA” option was chosen in the operating software to 
performing measurement of RNA concentration and purity. 1.0 μl of RNase-free water 
was used to clean the measurement pedestal. 1.0 μl of RNase-free water was initially 
measured and stored as blank in the operating software prior making a sample 
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measurement. Later, 1.0 μl of RNA sample was pipetted to the lower measurement 
pedestal and sampling arm was closed and clicked “measure”. A spectral measurement 
was initiated using the operating software on the computer. The sampling arm was 
opened when the measurement was completed and the sample from both upper and 
lower pedestal were wipe using delicate task wipers (Kimberly-Clark, Canada). Same 
procedures were performed for all the RNA samples.    
 
3.7.2 Agilent Bioanalyzer 
RNA sample integrity (RIN), purity and concentration of extracted total RNA 
for each sub-cell lines of A549, PC-3 and MCF7 were evaluated to increase accuracy of 
miRNA microarray expression profile, using the Agilent RNA 6000 Nano kit (Agilent 
Technologies, USA) on Agilent Bioanalyzer 2100 (Agilent Technologies, USA) 
following manufacturer’s protocol. First, chip priming station (Agilent Technologies, 
USA) was set up with syringe, the base plate adjusted to position C and the syringe clip 
was adjusted to the top position. 550.0 μl of RNA 6000 Nano gel matrix (Agilent 
Technologies, USA) were pipetted into spin filter and centrifuge at 1,500 x g for 10 min 
at room temperature. 65.0 μl of filtered gel was aliquoted into 0.5 ml RNase-free 
microfuge tubes. The aliquots were stored at 4ºC for 4 weeks. RNA 6000 Nano dye 
(Agilent Technologies, USA) was equilibrated to room temperature for 30 min and later 
was vortex for 10 s and spun down. 1.0 μl of dye was then added into a 65.0 μl aliquot 
of filtered gel, vortexed and spun down at 13,000 x g for 10 min at room temperature. A 
new RNA 6000 Nano Chip (Agilent Technologies, USA) was placed on the chip 
priming station. 9.0 μl of gel-dye mix was pipetted into the well marked with G and the 
lid of the chip priming station was closed. Plunger on the chip priming station was 
pressed until it is held by the clip and slowly pull back plunger to 1.0 ml position after 
5s. Chip priming station was opened and 9.0 μl of gel-dye mix was pipetted into the 
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well marked with G. 5.0 μl of RNA 6000 Nano marker was pipette in all 12 sample 
wells and in the well marked with ladder symbol. RNA ladder aliquot was preheated at 
70ºC for 2 min, then 1.0 μl of RNA ladder was pipetted into well marked with ladder 
symbol. 1.0 μl of RNA sample was loaded in each of the 12 sample wells. The chip was 
placed horizontally in the adapter of the IKA vortexer (Agilent Technologies, USA) and 
vortexed for 1 min at 2,400 rpm. The chip was inserted in the Agilent Bioanalyzer 2100 
within 5 min. RNA quality control analysis was performed using Eukaryote total RNA 
Nano assay class of Agilent 2100 expert software. The quality of RNA samples were 
assessed based on both RIN and 28S/18S rRNA ratios. 
 
3.8 MiRNA Microarrays 
 The differences in global miRNAs expression pattern between low and high 
invasiveness cancer sub-cell lines (A549, PC-3, MCF7) were assayed using GeneChip
®
 
miRNA Arrays (Affymetrix, USA) platform together with FlashTag
TM
 Biotin RNA 
labeling kit (Genesphere, USA) according to manufacturer’s protocol.  
 
3.8.1  RNA Poly (A) Tailing and Labelling 
 All reagents of FlashTag
TM
 Biotin RNA labeling kit were thawed according to 
protocol. 1.5 μg of total RNA was used as a starting material for poly (A) tailing. The 
volume of 1.5 μg of each total RNA sample was adjusted to 8.0 μl with nuclease-free 
water (Qiagen, Germany) and incubated on ice. Preparation of poly (A) tailing step was 
carried out by adding 2.0 μl of RNA Spike Control Oligos (Genesphere, USA), 1.5 μl of 
10X Reaction Buffer (Genesphere, USA), 1.5 μl of 25 mM MnCl2 (Genesphere, USA), 
1.0 μl of diluted ATP Mix (diluted in 1:500 with 1.0 mM Tris) (Genesphere, USA) and 
1.0 μl of PAP Enzyme (Genesphere, USA) to the 8.0 μl of 1.5 ng of total RNA. This 
15.0 μl cocktail was mixed gently without vortex and briefly spun down in a 
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microcentrifuge. The reaction cocktail was then incubated in a 37ºC heat block for 15 
min for poly (A) tailing step. 15.0 μl of tailed RNA was briefly spun and placed on ice 
before proceeding to FlashTag ligation.  
 4.0 μl 5X FlashTag Ligation Mix Biotin (Genesphere, USA) and 2.0 μl  of T4 
DNA Ligase (Genesphere, USA) were added into the poly (A) tailed RNA tube, mixed 
gently and was microfuged. The mixture was incubated at room temperature for 30 min 
for complete FlashTag ligation. 2.5 μl Stop Solution (Genesphere, USA) was added to 
the reaction cocktail to stop ligation reaction. 2.0 μl of the biotin-labeled sample was 
aliquoted into 1.5 ml microcentrifuge tubes for the Enzyme Linked Oligosorbent Assay 
(ELOSA) QC assay. The remaining 21.5μl biotin-labeled sample was kept in -20ºC 
immediately. 
 
3.8.2 ELOSA QC Assay 
 Before proceed to array hybridization, ELOSA QC assay was performed to 
verify the biotin labelling process by the FlashTag Biotin Labeling Kit. First, the 
ELOSA Spotting Oligos (Genesphere, USA) was diluted in 1:50 ratio with 1X PBS. 
75.0 μl of diluted ELOSA Spotting Oligos was added to each well of the plate or strip 
(total 8 wells: 6 well for samples, 1 well for positive control and 1 well for negative 
control). All the wells was covered with adhesive plate sealer and incubated overnight 
at 2-8°C.  
 After overnight incubation, the ELOSA Spotting Oligos solution was discarded 
into a sink. The wells were washed two times with 1X PBS, 0.02 % (v/v) Tween-20 
solution followed by blotted dry on papers. Each well was then blocked with 150.0 μl of 
5.0 % (w/v) BSA in 1X PBS solution and incubated for 1 h at room temperature. Later, 
BSA blocking solution was discarded and the wells plate was blotted dry. 
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 2.5 μl of 25.0 % dextran sulfate (Genisphere, USA) and 48.0 μl of solution of 
5X SSC, 0.05% SDS, 0.005% BSA added, gently vortexed and was briefly spun. 2.0 μl 
of ELOSA positive control (Genesphere, USA) was added to positive control labeled 
microcentrifuge tube, while 2.0 μl of 5X SCC, 0.05% (v/v) SDS, 0.005% (w/v) BSA 
was added to negative control labeled 1.5 ml microcentrifgue tube. 50.5 μl of master 
mix was added into each six 2.0 μl of the biotin-labeled samples, a positive control and 
a negative control labeled 1.5 ml microcentrifuge tube. The mixtures were vortexed 
gently and spun briefly. Each 52.5 μl of hybridization solution was loaded into each 
designated well and incubated for 1 h at room temperature. Hybridization solution was 
removed by expelling and washed vigorously for four times with 1X PBS, 0.02% (v/v) 
Tween 20 solution, then blotted dry.  
 0.5 μl of Streptavidin (SA)-HRP (Thermo Scientific, USA) was diluted in 2.0 ml 
of 5 % (w/v) BSA in 1X PBS with a dilution factor of 1:4000 for SA-HRP binding step. 
75.0 μl of the diluted SA-HRP was added into each well and incubated for 30 min at 
room temperature. SA-HRP was discarded into a sink after 30 min and vigorously 
washed 4 times with 1X PBS, 0.02% (v/v) Tween-20, then blotted dry. 100.0 μl of 
TMB substrate (Thermo Scientific, USA) was added to each well. The wells were 
covered and incubated at room temperature in the dark for 30 min. The intensity of blue 
color substrate in each well was observed after 30 min of incubation.  
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3.8.3 Hybridization of GeneChip
®
 miRNA Arrays 
 Hybridization of biotin-labeled RNA samples onto GeneChip
®
 miRNA Arrays 
were performed once FlashTag labeling process was verified by ELOSA QC assay. 20X 
Eukaryotic Hybridization Control (Genisphere, USA) was thawed and heated for 5 min 
at 65ºC. 21.5 μl of biotin-labeled sample was mixed with 50.0 μl 2X Hybridization Mix 
(Genisphere, USA), 10.0 μl of nuclease-free water, 5.0 μl of Deionized formamide 
(molecular biology grade) (Genisphere, USA), 10 μl of DMSO (Genisphere, USA), 5.0 
μl of 20X Eukaryotic Hydridization Control (Genisphere, USA) and 1.7 μl of Control 
Oligonucleotide B2, 3nM (Genisphere, USA). The sample mixture was gently mixed by 
flicking the tube and kept on ice. GeneChip
®
 miRNA arrays were unwrapped and 
warmed to room temperature for 10 min. Mark each array with a meaningful 
designation. The sample mixtures were incubated at 99ºC on heat block for 5 min, then 
45ºC in Affymetrix Hybridization Oven 640 (Affymetrix, USA) for 5 min. A 20.0 μl 
unfiltered type pipette tip was inserted into the upper right septum of GeneChip
®
 
miRNA arrays to allow for proper venting when hybridization cocktail is injected. 100.0 
μl sample was aspirated and injected into an array. The pipette tip was removed from 
the upper right septum of the array and covered both septa with 1/2" Tough-Spots 
(Biversified Biotech, USA) to minimize evaporation and prevent leaks. The arrays were 
loaded into hybridization oven trays and were incubated in Affymetrix Hybridization 
Oven 640 at 48°C and 60 rpm for 16 h. 
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3.8.4 Array Washing, Staining and Scanning 
 All arrays were taken out from oven after 16 h of hybridization and Tough-Spots 
were removed. The hybridization cocktail was extracted from each array and transferred 
to a new tube and stored at -80°C for long-term storage and later can be use for Array 
Rehybridization Procedure if necessary. Each array was filled with 100.0 μl of Array 
Holding Buffer and was equilibrated to room temperature before washing and staining 
steps. GeneChip Fluidics Station 450 was placed with a vial (amber) of 600.0 μl Stain 
Cocktail 1 in sample holder 1, a vial (amber) of 600.0 μl Stain Cocktail 2 in sample 
holder 2 and a vial (clear) of 800.0 μl Array Holding Buffer in sample holder 3. Arrays 
were washed and stained by Fluidics Station 450 using fluidics script FS450_0003 
program. After washing and staining, arrays were checked to make sure there are no air 
bubbles by manually filling the array with Array Holding Buffer. Both septa of arrays 
were covered with 3/8” Tough-Spots. The array glass surface was wiped with clean lab 
wipe, then hybridization signal of each array was detected by GeneChip
®
 scanner 3000 
7G (Affymetrix, USA).  
  
3.8.5 MiRNAs Expression Analysis 
 MiRNA microarray raw CEL file format data were imported into Partek 
Genomic Suite v 6.4 (Partek Inc., St. Louis, MO) using default parameters including 
robust-multichip average (RMA) for data normalization between triplicate samples, 
which includes background adjustments, normalization and summarization. A list of 
miRNAs with significantly differential expression between paired sub-cell lines were 
developed based on the criteria of gene expression ≥ 2.00 fold change and significant 
unadjusted p-values ≤0.05 using analysis of variance (ANOVA).  
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3.9 Quantitative Real-Time PCR  
 Quantitative Real-Time PCR was performed on the selected miRNAs of hsa-
miR-92b, hsa-miR-378, hsa-miR-671-5p and hsa-miR-1827 for miRNA microarray data 
validation. Total RNA from A549-I7 and A549-NI7 cells were extracted using Qiagen 
miRNeasy mini kit (Qiagen, Germany). Single-stranded cDNA was synthesized from 
total RNA (5.0 to 20.0 ng) using specific miRNA primers supplied together with 
TaqMan
®
 microRNA assay and TaqMan
®
 MicroRNA Reverse Transcription Kit 
(Applied Biosystems, USA). The specific miRNA primers of TaqMan
®
 miRNA assay 
(Applied Biosystems, USA) together with TaqMan
®
 Fast Advanced Master Mix 
(Applied Biosystems, CA, USA) were used to quantitate mature miRNAs of hsa-miR-
92b, hsa-miR-378, hsa-miR-671-5p and hsa-miR-1827 using CFX96 Real-Time PCR 
system (Bio-Rad, USA) according to standard manufacturer’s protocol.  
 
3.9.1 Reverse Transcription 
 Single-stranded cDNA was synthesized from total RNA using specific miRNA 
primers supplied together with TaqMan
®
 microRNA assay and TaqMan
®
 MicroRNA 
Reverse Transcription Kit (Applied Biosystems, USA) following the manufacturer’s 
optimized protocol and cycling condition.  The components of TaqMan
®
 MicroRNA 
Reverse Transcription Kit and reverse transcription (RT) primer of TaqMan
®
 
microRNA assay were thawed on ice. 5.0 to 30.0 ng total RNA (5.0 ng for hsa-miR-
92b, hsa-miR-378 and RNU6B, 10.0 ng for hsa-miR-671-5p, 30.0 ng for hsa-miR-1827) 
were diluted with nuclease-free water to final volume of 5.0 μl. Reverse transcription 
cocktail was prepared by mixing 0.15 μl dNTP mix, 1.00 μl of multiscribe RT enzyme, 
1.50 μl 10X RT buffer, 0.19 μl RNase Inhibitor, 4.16 μl nuclease free water, 5.0 μl of 
total RNA and 3 μl of specific miRNA RT primer into each labeled PCR tubes (Bio-
Rad, USA). These cocktail was mixed gently without vortex, centrifuged briefly and 
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incubated on ice until ready to load into thermal cycler. Reverse transcription was 
performed with the program in Table 3.1 CFX96 Real-Time PCR system (Bio-Rad, 
USA). The reaction volume was set at 15.0 μl and the PCR tubes were placed into the 
thermal cycler for reverse transcription. 
 
Table 3.1: Temperature and time for program for reverse transcription run.   
Step type Time (min) Temperature (ºC) 
Hold 30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
  
3.9.2 Real-Time PCR Amplification 
 Real-Time PCR amplification of mature miRNA from cDNA sample was 
performed using TaqMan microRNA assay (containing miRNA-specific forward and 
reverse PCR primer together with TaqMan MGB probe) together with the TaqMan
®
 
Fast Advanced Master Mix (Applied Biosystems, USA) following the manufacturer’s 
optimized protocol and cycling condition. A cocktail of 1.0 μl of cDNA, 5.0 μl TaqMan 
Fast advanced Master mix (Applied Biosystems, USA), 3.5 μl of nuclease free water 
and 0.5 μl of TaqMan miRNA assay (Applied Biosystems, USA) were mixed gently 
into each specific PCR reaction tubes then centrifuged briefly. Thermal-cycling of Real-
Time PCR amplification was ran according to the condition in Table 3.2. 
 
Table 3.2: Thermal cycling condition for Real-Time PCR amplification step. 
Step  
Enzyme 
activation 
PCR 
Hold 
Cycles (40 cycles) 
Denature Anneal/Extend 
Time (s) 20 3 20 
Temperature (ºC) 95 95 60 
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 Data were normalized against an RNU6B internal control, and fold changes of 
each miRNA was generated using 2
-∆∆Ct
. Pearson correlation plot was performed to 
assess the correlation between microarray and quantitative Real-Time PCR data. 
 
3.10  Pathway Enrichment Analysis 
 DIANA-mirPath (employed DIANA-microT-4.0 prediction data) was performed 
for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis 
on the differential expressed miRNAs in A549 (Papadopoulos et al., 2009). 10 miRNAs 
(miR-378, miR-671-5p, miR-25, miR-92b, miR-106b, miR-550, miR-629, miR-576-3p, 
miR-886-5p, miR-487b) were input for KEGG pathways enrichment except of miR-
1827 which was not in the DIANA-mirPath gene input list. Top eight metastasis related 
KEGG pathways were filtered out from the KEGG pathways list with a -ln(p-value) 
score of  ≥ 3.00. Due to the scarce number of miRNA* included in the DIANA-mirPath 
algorithm (miR-25*, miR-106b*, miR-550* and miR-629* were not included), the 
guided strands (miR-25, miR-106b, miR-550 and miR-629) were selected from the 
DIANA-mirPath gene input list for KEGG pathways enrichment to obtain a more 
comprehensive analysis. Later, the top eight metastasis-related KEGG pathways were 
combined with the target prediction data from TargetScan 5.2  of total context score of 
≤ -0.10 with regardless of the conservation site (http://www.targetscan.org/vert_50/) 
and DIANA-microT 4.0 (Maragkakis et al., 2011) of miTG score of ≥ 0.20 to 
investigate the possible molecular components of signalling network in A549 cancer 
metastasis. MiRNAs* were included into the signalling pathway analysis based on the 
DIANA-microT 4.0 prediction data where this algorithm has miRNAs* (miR-25*, miR-
106b*, miR-550* and miR-629*) in the gene input list. A hypothetical signalling 
network was proposed based on the KEGG pathways from DIANA-mirPath that 
combined with the target prediction data of DIANA-microT 4.0 and TargetScan 5.2 
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with a -ln(p-value) score of  ≥ 3.00, miTG score of ≥ 0.20 and total context score of  ≤ -
0.10.   
 
3.11 Statistical Analysis 
 All data were collected in triplicates with the exception of wound healing assays 
which were carried out in four replicates. Statistical analyses were performed using a 
one-tailed Student’s t test. Differences with p-values of ≤0.05 were considered 
significant.  
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CHAPTER 4: RESULTS 
 
4.1  Establishment of High and Low Invasiveness Cancer Sub-Cell Lines with 
Similar Proliferation Properties and Distinctly Different Invasion and Migration 
Attributes 
4.1.1 Serial Selection of High and Low Invasiveness Sub-Cell Lines 
 In order to study cancer metastasis, high and low invasiveness cancer sub-cell 
lines were established from parental human lung cancer cell lines A549, prostate cancer 
cell line PC-3, two breast cancer cell lines MDA-MB-231 and MCF7 using sequential 
transwell invasion assay. The high invasiveness cells successfully invaded through 
Matrigel for all 7 rounds were designated as A549-I7, PC-3-I7, MCF7-I7 and MDA-
MB-231-I7 sub-cell lines, whilst the low invasiveness cancer cells failed to invade 
through Matrigel for all 7 rounds of selection were designated as A549-NI7, PC-3-NI7, 
MCF7-NI7 and MDA-MB-231-NI7 sub-cell lines (Figure 4.1).  
 All high invasiveness sub-cell lines were also observed with weakened adhesion 
properties to culture plates during sub-culturing. High invasiveness sub-cell lines took 
shorter time to detached from the culture plate upon exposure of trypsin compared to 
low invasiveness sub-cell lines and parental A549 cells (result not shown). 
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Figure 4.1: Diagram showing high (A549-I7, PC-3-I7, MCF7-I7 and MDA-MB-231-
I7) and low (A549-NI7, PC-3-NI7, MCF7-NI7 and MDA-MB-231-NI7) invasiveness 
sub-cell lines were established from each parental cell lines of A549, PC-3, MCF7 and 
MDA-MB-231 using serial transwell invasion approach. 
  
4.1.2  Transwell Invasion Assay 
 After serial selection of high and low invasiveness sub-cell lines from parental 
cell lines, invasion properties of each selected sub-cell lines were validated with 
transwell invasion assay. Number of methylene blue stained invaded cells per field was 
calculated based on the average of eight random transwell invasion insert membrane at 
200X magnification fields for each sub-cell lines. Each selected high invasiveness sub-
cell lines were validated with greater invasive capacities compared to the low 
invasiveness sub-cell lines (Figure 4.2 to 4.9). 
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4.1.2.1 Transwell Invasion Assay of A549  
An increased number of invaded A549-I7 cells compared to A549-NI7 cells 
were observed in Figure 4.2 using transwell invasion assay. A549-I7 was significantly 3 
fold greater in the capacity to invade through Matrigel coated transwell membrane 
insert compared to A549-NI7 with p-value of 0.023 (Figure 4.3). 
 
  
Figure 4.2: Representative cell fields of methylene blue stained invaded cells on the 
bottom membranes of Matrigel transwell invasion insert for A549-I7 and A549-NI7 at 
200X magnification.  
 
 
 
Figure 4.3: A bar graph represents the average invaded cells per field of A549-I7 and 
A549-NI7 with data presented as mean + SEM of three independent experiments with 
p-value <0.05.  
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4.1.2.2 Transwell Invasion Assay of PC-3 
 An increased number of invaded PC-3-I7 cells compared to PC-3-NI7 cells were 
observed in Figure 4.4 using transwell invasion assay. PC-3-I7 was significantly 3.5 
fold greater in the capacity to invade through Matrigel coated transwell membrane 
insert compared to PC-3-NI7 with p-value of 0.014 (Figure 4.5). 
 
  
Figure 4.4: Representative cell fields of methylene blue stained invaded cells on the 
bottom membranes of Matrigel transwell invasion insert for PC-3-I7 and PC-3-NI7 at 
200X magnification. 
 
 
 
Figure 4.5: A bar graph represents the average invaded cells per field of PC-3-I7 and 
PC-3-NI7 with data presented as mean + SEM from three independent experiments with 
p-value <0.05.  
 
 
 
 
 
 
P= 0.014
26
90
0
20
40
60
80
100
PC-3-I7 PC-3-NI7
sub-cell lines
in
v
a
d
e
d
 c
e
ll
s
 p
e
r 
fi
e
ld
  
PC-3-I7 PC-3-NI7 
 58 
4.1.2.3 Transwell Invasion Assay of MCF7 
 An increased number of invaded MCF7-I7 cells compared to MCF7-NI7 cells 
were observed in Figure 4.6 using transwell invasion assay. MCF-I7 was significantly 3 
fold greater in the capacity to invade through Matrigel coated transwell membrane 
insert compared to MCF7-NI7 with p-value of 0.027 (Figure 4.7). 
 
  
Figure 4.6: Representative cell fields of methylene blue stained invaded cells on the 
bottom membranes of Matrigel transwell invasion insert for MCF7-I7 and MCF7-NI7 at 
200X magnification.  
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Figure 4.7: A bar graph represents the average invaded cells per field of MCF7-I7 and 
MCF7-NI7 with data presented as mean + SEM from three independent experiments 
with p-value <0.05. 
 
 
 
 
 
 
MCF7-I7 MCF7-NI7 
 59 
4.1.2.4 Transwell Invasion Assay of MDA-MB-231 
 An increased number of invaded MDA-MB-231-I7 cells compared to MDA-
MB-231-NI7 cells were observed in Figure 4.8 using transwell invasion assay. MDA-
MB-231-I7 was significantly 3.4 fold greater in the capacity to invade through Matrigel 
coated transwell membrane insert compared to MDA-MB-231-NI7 with p-value of 
0.044 (Figure 4.9). 
 
  
Figure 4.8: Representative cell fields of methylene blue stained invaded cells on the 
bottom membranes of Matrigel transwell invasion insert for MDA-MB-231-I7 and 
MDA-MB-231-NI7 at 200X magnification.   
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Figure 4.9: A bar graph represents the average invaded cells per field of MDA-MB-
231-I7 and MDA-MB-231-NI7 with data presented as mean + SEM from three 
independent experiments with p-value <0.05.  
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4.1.3 Wound Healing Assay 
Wound healing assay was used to validate migratory potential of each selected 
sub-cell lines. The percentage of wound healing for A549-I7 and A549-NI7 with data 
presented as mean + SEM from four independent experiments using T-Scratch software.  
Each selected high invasiveness sub-cell lines were validated with higher migration 
abilities compared to the low invasiveness sub-cell lines (Figure 4.10 to 4.17). 
 
4.1.3.1 Wound Healing Assay of A549 
A549-I7 was observed to close the scratch wound faster than A549-NI7 at 28 h 
time point (Figure 4.10). A549-I7 has 2.8 fold greater migration capacity as compared 
to A549-NI7 with p-value of 0.003 (Figure 4.11). 
 
   A549-I7       A549-NI7 
     
          
 
Figure 4.10: Migrations of A549-I7 and A549-NI7 cells into the wound were captured 
at 0 h and 28 h time at 100X magnification.  
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Figure 4.11: A bar chart represents the percentage of wound healing for A549-I7 and 
A549-NI7 with data presented as mean + SEM from four independent experiments.  
 
4.1.3.2 Wound Healing Assay of PC-3 
PC-3-I7 was observed to close the scratch wound faster than PC-3-NI7 at 28 h 
time point (Figure 4.12). PC-3-I7 has 1.8 fold greater migration capacity as compared to 
PC-3-NI7 with p-value of 0.002 (Figure 4.13). 
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Figure 4.12: Migrations of PC-3-I7 and PC-3-NI7 cells into the wound were captured 
at 0 h and 28 h time at 100X magnification. 
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Figure 4.13: A bar chart represents the percentage of wound healing for PC-3-I7 and 
PC-3-NI7 with data presented as mean + SEM from four independent experiments.  
 
4.1.3.3 Wound Healing Assay of MCF7 
MCF7-I7 was observed to close the scratch wound faster than MCF7-NI7 at 23 
h time point (Figure 4.14). MCF7-I7 has 2.0 fold greater migration capacity as 
compared to MCF7-NI7 with p-value of 0.004 (Figure 4.15). 
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Figure 4.14: Migrations of MCF7-I7 and MCF7-NI7 cells into the wound were 
captured at 0 h and 23 h time at 100X magnification. 
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Figure 4.15: A bar chart represents the percentage of wound healing for MCF7-I7 and 
MCF7-NI7 with data presented as mean + SEM from four independent experiments.  
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4.1.3.4 Wound Healing Assay of MDA-MB-231 
MDA-MB-231-I7 was observed to close the scratch wound faster than MDA-
MB-231-NI7 at 28 h time point (Figure 4.16). MDA-MB-231-I7 has 1.8 fold greater 
migration capacity as compared to MDA-MB-231-NI7 with p-value of 0.018 (Figure 
4.17). 
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Figure 4.16: Migrations of MDA-MB-231-I7 and MDA-MB-231-NI7 cells into the 
wound were captured at 0 h and 23 h time at 100X magnification. 
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Figure 4.17: A bar chart represents the percentage of wound healing for MDA-MB-
231-I7 and MDA-MB-231-NI7 with data presented as mean + SEM from four 
independent experiments.  
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4.1.4 Cell Proliferation Assay 
Cell proliferation assay was used to validate proliferation rate of the selected 
sub-cell lines. Consistent cell proliferation rate between each parental, high 
invasiveness and low invasiveness sub-cell lines were observed (Figure 4.18 to 4.25) 
(Appendix 5.2). 
 
4.1.4.1 Cell Proliferation Assay of A549 
 In Figure 4.18, number of viable cells on the log phase of the growth curve (day 
4) was used to calculate the doubling time of A549-I7, A549-NI7 and A549 using 
equation 3.4. Consistent cell proliferation rate between A549-I7, A549-NI7 and A549 
with doubling time of approximately 19 h were observed (Figure 4.19). 
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Figure 4.18: Cell proliferation curve for A549-I7, A549-NI7 and A549 over 7 days 
with number of viable cells on each day presented as mean + SEM from the three 
individual experiments. 
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Figure 4.19: A bar chart representing the doubling time (h) for A549-I7, A549-NI7 and 
A549 are presented as mean + SEM from the three individual experiments. 
 
4.1.4.2 Cell Proliferation Assay of PC-3 
 In Figure 4.20, number of viable cells on the log phase of the growth curve (day 
4) was used to calculate the doubling time of PC-3-I7, PC-3-NI7 and PC-3 using 
equation 3.4. Consistent cell proliferation rate between PC-3-I7, PC-3-NI7 and PC-3 
with doubling time of approximately 18 h were observed (Figure 4.21). 
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Figure 4.20: Cell proliferation curve for PC-3-I7, PC-3-NI7 and PC-3 over 7 days with 
number of viable cells on each day presented as mean + SEM from the three individual 
experiments. 
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Figure 4.21: A bar chart representing the doubling time (h) for PC-3-I7, PC-3-NI7 and 
PC-3 are presented as mean + SEM from the three individual experiments. 
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4.1.4.3 Cell Proliferation Assay of MCF7 
 In Figure 4.22, number of viable cells on the log phase of the growth curve (day 
4) was used to calculate the doubling time of MCF7-I7, MCF7-NI7 and MCF7 using 
equation 3.4. Consistent cell proliferation rate between MCF7-I7, MCF7-NI7 and 
MCF7 with doubling time of approximately 17 h were observed (Figure 4.23). 
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Figure 4.22: Cell proliferation curve for MCF7-I7, MCF7-NI7 and MCF7 over 7 days 
with number of viable cells on each day presented as mean + SEM from the three 
individual experiments. 
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Figure 4.23: A bar chart representing the doubling time (h) for MCF7-I7, MCF7-NI7 
and MCF7 presented as mean + SEM from the three individual experiments. 
 
4.1.4.4 Cell Proliferation Assay of MDA-MB-231 
 In Figure 4.24, number of viable cells on the log phase of the growth curve (day 
4) was used to calculate the doubling time of MDA-MB-231-I7, MDA-MB-231-NI7 
and MDA-MB-231 using equation 3.4. Consistent cell proliferation rate between MDA-
MB-231-I7, MDA-MB-231-NI7 and MDA-MB-231 with doubling time of 
approximately 17 h were observed (Figure 4.25). 
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Figure 4.24: Cell proliferation curve for MDA-MB-231-I7, MDA-MB-231-NI7 and 
MDA-MB-231 over 7 days with number of viable cells on each day presented as mean 
+ SEM from the three individual experiments. 
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Figure 4.25: A bar chart representing the doubling time (h) for MDA-MB-231-I7, 
MDA-MB-231-NI7 and MDA-MB-231 are presented as mean + SEM from the three 
individual experiments. 
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4.2 Identification and Validation of Differentially Expressed Metastasis-
Related MiRNAs 
4.2.1 Total RNA Quality Control Using Agilent Bioanalyzer 
 Only A549, PC-3 and MCF7 were selected to proceed to total RNA extraction 
for miRNA microarray analysis. Both MCF7 and MDA-MB-231 are breast cancer cell 
lines, MDA-MB-231 was filtered out due to the reasons of less migration and invasion 
capacities as compared to MCF7.  
 Gel matrix electrophoresis images of RNA samples by bioanalyzer analysis are 
shown in Figure 4.26. In Table 4.1, RNA integrity number (RIN) are listed for each four 
replicates of PC-3-I7, PC-3-NI7, A549-I7, A549-NI7, MCF7-I7 and MCF7-NI7 RNA 
samples. The RIN values of all samples were obtained between 8.9 to 9.7, which are 
above the minimum recommended RIN value of 7. Only three RNA samples for each 
sub-cell lines with better RNA quality were picked for miRNA microarray analysis 
based on RIN value and 28S/18S rRNA ratio.  
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(A) 
 
(B) 
 
Figure 4.26: Bioanalyzer analysis of four replicates of total RNA extracted from high 
and low invasiveness sub-cell lines of PC-3, A549 and MCF7. (A) PC-3-I7, PC-3-NI7 
and A549-I7; (B) A549-NI7, MCF7-I7 and MCF7-NI7. 
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Table 4.1: RIN range (0.0 min. to 10.0 max.) of  total RNAs extracted from high and 
low invasiveness sub-cell lines of PC-3, A549 and MCF7 using Agilent Bioanalyzer 
2100 RNA 6000 Nano kit. 
Sub-cell line Replicate 
RNA Integrity Number 
(RIN) 
Used for miRNA 
microarray 
PC-3-I7 
 
1 9.30 Yes 
2 9.50 Yes 
3 9.20 Yes 
4 9.30 No 
PC-3-NI7 
 
1 9.30 Yes 
2 9.20 Yes 
3 9.00 Yes 
4 8.90 No 
A549-I7 
1 9.40 Yes 
2 9.40 Yes 
3 9.30 No 
4 9.60 Yes 
A549-NI7 
1 9.30 No 
2 9.60 Yes 
3 9.70 Yes 
4 9.50 Yes 
MCF7-I7 
1 9.70 Yes 
2 9.40 No 
3 9.40 Yes 
4 9.60 Yes 
MCF7-NI7 
1 9.50 Yes 
2 9.50 No 
3 9.60 Yes 
4 9.60 Yes 
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4.2.2 MiRNA Microarray Analysis 
 In order to investigate the miRNAs potentially involved in lung, prostate and 
breast cancer invasion and migration, we examined global miRNA expression in both 
paired cell lines of A549, PC-3 and MCF7 using the miRNA microarray platform, 
GeneChip
®
 miRNA Array. RNA samples were confirmed to be successfully 
biotinylated as seem by the blue substrate color intensity observed after 30 min of 
incubation using ELOSA assay before sample hybridization on GeneChip
®
 miRNA 
Array (result not shown). These arrays revealed the expression of nearly thousand of 
human miRNAs in each sub-cell lines. CEL files were imported into Partek Genomic 
Suite v 6.4 (Partek Inc., St. Louis, MO) for analyses. Identifying differentially 
expressed miRNAs between paired sub-cell lines involved three major steps of 
normalization, preliminary analysis and statistical analysis. Normalization of miRNA 
array data was performed as robust-multichip average (RMA) for data normalization 
between triplicate samples which includes background adjustments, normalization and 
summarization.  Principle component analysis (PCA) was carried out before statistical 
analysis. Later, a list of miRNAs with significantly differential expression between 
paired sub-cell lines were developed based on the criteria of gene expression ≥ 2.00 fold 
change and significant unadjusted p-values ≤ 0.05 using analysis of variance 
(ANOVA).  
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4.2.2.1 MiRNA Microarray Analysis of A549  
 The A549 microarray data distribution pattern was relatively close as shown in 
PCA plots of Figure 4.27. A total of 11 out of 846 human miRNAs were found to be 
differentially expressed with a fold change of ≥ 2.0 between A549-I7 and A549-NI7 
with p-value < 0.05. 6 miRNAs (miR-378, miR-671-5p, miR-25*, miR-92b, miR-106b* 
and miR-550*) were up-regulated with miR-378 displaying the highest fold change in 
A549-I7, while 5 miRNAs (miR-629*, miR-576-3p, miR-886-5p, miR-487b and miR-
1827) were down-regulated in A549-I7 with miR-629* displaying the highest fold 
change (Table 4.2). MiRNA* known as passenger strand or complementary strand of 
the double-stranded RNA duplexes. Among 11 differentially expressed A549 
metastasis-related miRNAs, 4 of them are miRNA*.  
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Figure 4.27: Three different plane views of PCA of A549-I7 (red) and A549-NI7 (blue) displayed the distribution of microarray data replicates. 
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Table 4.2: Differentially expressed metastasis-related miRNAs between A549-I7 and 
A549-NI7 with p-value ≤ 0.05 and fold change ≥ 2.0 filtering using Partek® Genomics 
Suite
TM
 software.  
miRNA Expression 
in A549-I7 
microRNAs 
Fold change 
†
 
(A549-I7/A549-NI7) 
p-value 
Up-regulated 
miR-378 3.389 0.033 
miR-671-5p 2.852 0.001 
miR-25* 2.840 0.050 
miR-92b 2.600 0.004 
miR-106b* 2.500 0.011 
miR-550* 2.280 0.046 
Down-regulated 
miR-629* -2.915 0.007 
miR-576-3p -2.780 0.038 
miR-886-5p -2.538 0.013 
miR-487b -2.231 0.001 
miR-1827 -2.142 0.004 
†
 Positive values denote up-regulation; negative values denote down-regulation. 
 
 
4.2.2.2 MiRNA Microarray Analysis of PC-3 
 The PC-3 microarray data distribution pattern was relatively close as shown in 
PCA plots of Figure 4.28. A total of 20 out of 846 human miRNAs were found to be 
differentially expressed with a fold change of ≥ 2.0 between PC-3-I7 and PC-3-NI7 
with p-value < 0.05. 4 miRNAs (mir-129-1*, mir-606, mir-34b* and mir-19b-1) were 
up-regulated with miR-129-1* displaying the highest fold change in PC-3-I7, while 15 
miRNAs (miR-320a, miR-132*, miR-744, miR-654, miR-409, miR-1180, miR-503, 
miR-423, miR-382, miR-487b, miR-409, miR-210, miR-342, miR-134, miR-379 and 
miR-708) were down-regulated in PC-3-I7 with miR-708 displaying the highest fold 
change (Table 4.3). Among 20 differentially expressed A549 metastasis-related 
miRNAs, 3 of them are miRNA* which also known passenger strand or complementary 
strand of the double-stranded RNA duplexes.  
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Figure 4.28: Three different plane views of PCA of PC-3-I7 (red) and PC-3-NI7 (blue) displayed the distribution of microarray data replicates.
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Table 4.3: Differentially expressed metastasis-related miRNAs between PC-3-I7 and 
PC-3-NI7 with p-value ≤ 0.05 and fold change ≥ 2.0 filtering using Partek® Genomics 
Suite
TM
 software. 
miRNA Expression 
in PC-3-I7 
miRNAs 
Fold change 
†
 
(PC-3-I7/PC-3-NI7) 
p-value 
Up-regulated 
miR-129-1* 3.227 0.026 
miR-606 2.784 0.005 
miR-34b* 2.263 0.001 
miR-19b-1 2.123 0.013 
Down-regulated 
miR-320a -2.014 0.004 
miR-132* -2.029 0.026 
miR-744 -2.206 0.019 
miR-654 -2.208 0.041 
miR-409 -2.287 0.011 
miR-1180 -2.330 0.045 
miR-503 -3.051 0.044 
miR-423 -3.528 0.016 
miR-382 -3.584 0.005 
miR-487b -3.636 0.003 
miR-409 -4.358 0.000 
miR-210 -4.862 0.003 
miR-342 -6.492 0.034 
miR-134 -7.168 0.002 
miR-379 -7.530 0.000 
miR-708 -9.256 0.001 
†
 Positive values denote up-regulation; negative values denote down-regulation. 
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4.2.2.3 MiRNA Microarray Analysis of MCF7 
 The MCF7 microarray data distribution pattern was relatively close as shown in 
PCA plots of Figure 4.29. A total of 32 out of 846 human miRNAs were found to be 
differentially expressed with a fold change of ≥ 2.0 between MCF7-I7 and MCF7-NI7 
with p-value < 0.05. 22 miRNAs (miR-302c*, miR-496, miR-135b, miR-324, miR-
181d, miR-1252, miR-93, miR-376c, miR-30b*, miR-616, miR-664, miR-891b, miR-
448, miR-543, miR-624, miR-624*, miR-1234, miR-199a-1, miR-578, miR-513a-1, 
miR-603 and miR-1231) were up-regulated with miR-302*c displaying the highest fold 
change in MCF7-I7, while 10 miRNAs (miR-183, miR-1827, miR-129-2, miR-1246, 
miR-519e*, miR-1247, miR-365a, miR-503, miR-152 and miR-10a) were down-
regulated in MCF7-I7 with miR-10a displaying the highest fold change (Table 4.4). 
Among 32 differentially expressed A549 metastasis-related miRNAs, 3 of them are 
miRNA* which also known as passenger strand or complementary strand of the double-
stranded RNA duplexes. 
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Figure 4.29: Three different plane views of PCA of MCF7-I7 (red) and MCF7-NI7 (blue) displayed the distribution of microarray data replicates. 
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Table 4.4: Differentially expressed metastasis-related miRNAs between MCF7-I7 and 
MCF7-NI7 with p-value ≤ 0.05 and fold change ≥ 2.0 filtering using Partek® Genomics 
Suite
TM
 software. 
miRNA Expression 
in MCF7-I7 
miRNAs  
Fold change 
†
 
(MCF7-I7/MCF7-NI7) 
p-value 
Up-regulated 
miR-302c* 11.280 0.034 
miR-496 9.880 0.027 
miR-135b 9.478 0.001 
miR-324 8.572 0.015 
miR-181d 5.592 0.028 
miR-1252 5.272 0.027 
miR-93 5.098 0.044 
miR-376c 4.961 0.026 
miR-30b* 4.547 0.028 
miR-616 4.249 0.003 
miR-664 3.989 0.038 
miR-891b 3.931 0.017 
miR-448 3.618 0.004 
miR-543 3.307 0.023 
miR-624 3.032 0.012 
miR-624* 2.913 0.003 
miR-1234 2.732 0.020 
miR-199a-1 2.658 0.001 
miR-578 2.619 0.005 
miR-513a-1 2.233 0.007 
miR-603 2.219 0.000 
miR-1231 2.139 0.018 
Down-regulated 
miR-183 -2.575 0.008 
miR-1827 -2.777 0.017 
miR-129-2 -4.466 0.036 
miR-1246 -4.798 0.046 
miR-519e* -6.161 0.017 
miR-1247 -7.007 0.021 
miR-365a -9.723 0.001 
miR-503 -14.291 0.041 
miR-152 -15.518 0.000 
miR-10a -137.587 0.001 
†
 Positive values denote up-regulation; negative values denote down-regulation. 
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4.2.3  Quantitative Real-Time PCR 
 Out of three cell lines conducted, A549 were chosen for further analysis because 
less research work were carried out on miRNAs in lung cancer metastasis. Also, 
miRNAs such as miR-378 were found to be involved in regulating cancer metastasis in 
a recent research (Chen et al., 2011). RNA concentration and the quality of RNA 
extracted from A548 were assessed by Nanodrop Spectrophotometer in Table 4.5. 
Microarray data of A549 were validated via Real-Time PCR on 4 representative 
miRNAs (miR-92b, miR-378, miR-671-5p and miR-1827) using RNU6B as an 
endogenous control (Figure 4.30).  
 
4.2.3.1 Nanodrop Spectrophotometer 
 RNA samples were extracted from A549-I7 and A549-NI7. All RNA samples 
were diluted in 1:10 ratio with nuclease-free water before RNA quantification using 
Nanodrop Spectrophotometer 2000 (Thermo Scientifc, USA). RNA purity can be 
assessed based on the absorbance ratio of 260/280 in Table 4.5. 
 
Table 4.5: RNA concentration, absorbance and absorbance ratio of both A549-I7 and 
A549-NI7 using Nanodrop Spectrophotometer 2000 in three replicates. 
RNA 
sample 
Replicate 
Concentration 
(ng/μl) 
A260 A280 A260/A280 A260/A230 
A549-I7 1 24.7 0.616 0.301 2.05 2.13 
A549-I7 2 32.1 0.802 0.393 2.04 2.28 
A549-I7 3 48.8 1.320 0.591 2.07 2.08 
A549-NI7 1 57.4 1.436 0.702 2.04 2.21 
A549-NI7 2 40.7 1.017 0.479 2.12 2.15 
A549-NI7 3 55.6 1.466 0.711 2.06 2.20 
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4.2.3.2 Pearson Correlation Plot  
 Real-Time PCR data were in accordance with expression pattern of A549-I7 in 
relative to A549-NI7 with miRNA microarray data.  Pearson correlation showed a high 
and positive correlation (R=0.809) between data generated by miRNA microarray and 
qRT-PCR, which confirmed the validity of all miRNA expression patterns obtained 
(Figure 4.31). 
 
0.0
0.5
1.0
1.5
2.0
2.5
miR-92b miR-378 miR-671-5p miR-1827
microRNAs
fo
ld
 c
h
a
n
g
e
 (
2
-∆
∆
C
t )
 
Figure 4.30: Four differentially expressed miRNAs (miR-92b, miR-378, miR-671-5p 
and miR-1827) between A549-I7 and A549-NI7 validated using Real-Time PCR. 
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 Figure 4.31: A pearson’s correlation plot between miRNA microarray and Real-Time 
PCR data.  
 
4.3 Predicted Targets of A549 Metastasis-Related MiRNAs Enriched in 
Metastasis-Related Signalling Pathways 
4.3.1 Pathways Enrichment Analyses 
 A miRNA potentially act on several mRNA targets, that is, a single mRNA can 
be targeted by multiple miRNAs (Esquela-Kerscher and Slack, 2006). Based on 
growing evidences of co-operative miRNA activity, it is essential to perform pathway 
enrichment analysis to investigate combinatorial effects of all dysregulated miRNAs in 
cancer metastasis progression (Dombkowski et al., 2011). Since combinatorial effects 
of different pathways govern the physiological and pathological outcomes of cancer 
progression, it is essential to have all miRNAs included for analysis using DIANA-
mirPath (employed DIANA-microT-4.0 algorithm). DIANA-mirPath enriches the 
KEGG pathways downstream of differentially expressed miRNAs between A549-I7 
and A549-NI7 cells, hence revealing the relationship between individual miRNAs and 
their influence on targeted genes. A descending list of the top eight cancer metastasis-
related KEGG pathways based on a -ln(p-values) score threshold of ≥ 3.00 of DIANA-
mirPath (DIANA-microT-4.0), which corresponded to A549-I7 lung cancer invasion 
properties are summarized in Table 4.6. Enrichment of genes involved in cancer 
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metastasis-related pathways indicated possible involvement of Wnt/planar cell polarity 
(PCP), TGF-β, mitogen-activated protein kinase (MAPK), focal adhesion, adherens 
junction, mammalian target of rapamycin (mTOR), ECM receptor interaction and actin 
cytoskeleton regulation signalling pathways in cancer invasion and migration by 
dysregulated miRNAs. 
 
Table 4.6: Top eight descending list of metastasis-related KEGG pathways that were 
predicted to be contribute in A549 cancer metastasis using the DIANA-mirPath 
algorithm employing DIANA-microT-4.0 as a prediction software with a –ln(p-value) 
threshold of ≥ 3.00. 
KEGG pathway -ln(p-value)
 †
 
Wnt signalling pathway 23.63 
TGF-β signalling pathway 15.94 
MAPK signalling pathway  14.70 
Focal adhesion 9.60 
Adherens junctions 8.08 
mTOR signalling pathway  7.01 
ECM receptor interaction 4.12 
Regulation of actin cytoskeleton 3.53 
†
Input gene list of 10 miRNAs (miR-378, miR-671-5p, miR-25, miR-92b, miR-106b, 
miR-550, miR-629, miR-576-3p, miR-886-5p, miR-487b) except of miR-1827 which was 
not in the DIANA-mirPath algorithm gene input list. 
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 In Figure 4.32, a hypothetical signalling network showing the interaction of 
miRNAs and their putative targets in regulating A549 lung cancer metastasis using 
DIANA-mirPath (DIANA-microT-4.0) together with DIANA microT 4.0 and 
TargetScan 5.2 database with a -ln(p-value) score of  ≥ 3.00, miTG score of ≥ 0.20 and 
total context score of ≤ -0.10. All these miRNAs were proposed to act in concert to 
modulating pathways of non-canonical Wnt/PCP, TGF-β, integrin-FAK-Src, MAPK 
and mTOR signaling cascades to promote lung cancer migration and invasion. As 
negative regulators, targets of up-regulated miRNAs were largely found to be inhibitors 
of cancer progression and metastasis such as mRNAs encoding Smad7, Smad ubiquitin 
regulatory factors (Smurf), prickle and secreted frizzled-related protein (sFRP), while 
targets of down-regulated miRNAs were mainly of a pro-metastatic nature such as 
mRNAs encoding TGF-β, Wnt, frizzled (Fzd), KAI1 COOH-terminal interacting 
tetraspanin (KITENIN) and integrins. 
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Figure 4.32: A hypothetical signalling network showing the interaction of miRNAs and their putative targets in regulating A549 lung cancer 
metastasis.  
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CHAPTER 5: DISCUSSION 
 
 Cancer metastasis involved complex process where primary cancerous cells 
successfully passed through all the sequential steps of detachment, migration, adhesion, 
invasion of ECM, extravasation to a distant organ parenchyma, angiogenesis and 
growth at secondary site (Ma & Weinberg, 2008). Even though past studies have 
focused on issues of metastasis, there are still no major breakthroughs in terms of 
preventing cancer metastasis. Thus, there is a great need to understand the molecular 
alterations in cancer invasion and metastasis that confer a poor prognosis.  
 In order to have a suitable cell line model to study the cancer metastatic process, 
we had established four set of high and low invasiveness cancer sub-cell lines from 
A549, PC-3, MCF7 and MDA-MB-231 cell lines with different potential in invasion 
and migration properties using serial transwell invasion approach (Figure 4.1 to 4.17). 
As the proliferation capacity of the parental and sub-cell lines were found to be the 
same, it might not contribute to the variation of invasion and migration properties of the 
sub-cell lines (Figure 4.18 to 4.25). Also, invasiveness of sub-cell lines were observed 
to possess weakened adhesion properties to cultures plates upon exposure to trypsin 
compared to low invasiveness cancer sub-cell lines and parental cell lines (result not 
shown). This may indicate that the cells from the highly invasive sub-cell lines has less 
adherence ability to cells or the ECM, which may facilitate them to break away easily 
and migrate or invade through the ECM. 
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 Since the identification of miRNAs as master regulators of gene expression 
networks and recent implications of miRNAs in metastatic progression, therefore 
identification and characterization of miRNAs involved in cancer invasion and 
metastasis have been of great importance (Bracken et al., 2009; Wentz-Hunter and 
Potashkin, 2011). MiRNA microarray analyses were performed to identify the 
involvement of miRNAs in cancer invasion and migration of lung, breast and prostate 
cancer cell lines. We obtained a list of differential expressed metastasis-related miRNAs 
for A549, PC-3 and MCF7. Given that each paired sub-cell lines with different 
metastatic potential were derived from a single parental cell line with similar genetic 
background, therefore the differentially expressed miRNAs population between the 
paired sub-cell lines might play a role in cancer invasion and migration. 
 
5.1 Hypothetical A549 Lung Cancer Metastasis Signalling Network Model   
 Given that 75% to 85% of diagnosed lung cancers to-date are non-small cell 
lung cancer (NSCLC) with an increasing histopathological portion of it being 
adenocarcinoma subtypes (Koparal and Zeytinoglu, 2003; Berghmans et al., 2011), thus 
a NSCLC adenocarcinoma cell line A549 was chosen in this study.  
 A549 miRNA microarray data revealed 4 out of 6 up-regulated miRNAs (miR-
671-5p, miR-25*, miR-106b* and miR-550*) were found located at chromosome 7. 
This might indicate that the cell population of A549-I7 had more than 2 copies of 
chromosomes 7 since cytogenetics analysis revealed that A549 is an aneuploid human 
cell line that consist of multiple cells clones averaging a total of 62 to 72 of 
chromosomes in cells (Isaka et al., 2003). MiRNA microarray data also revealed 4 
miRNAs* strands (miR-25*, miR-106b*, miR-550* and miR-629*) out of 11 
differentially expressed miRNAs (Table 4.2). During miRNA biogenesis, one strand of 
short RNA duplex is preferentially selected for entry into the silencing complex, 
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whereas the other strand known as miRNA* strand or passenger RNA is typically 
degraded and commonly viewed as non-functional. However, certain miRNA* strands 
have been reported as highly expressed mature functional miRNAs, which alters the 
overall miRNA/miRNA* ratio during the development of vertebrates (Guo and Lu, 
2010; Yang et al., 2011). Therefore, we are also reporting these four significantly 
expressed miRNA* in the pathway analysis to determine whether they might have an 
important functional role in regulating cancer metastasis.    
 Some of the differentially expressed miRNAs have been reported to play a role 
in regulating cancer metastasis progression. For example, in a recent research work 
done by Chen and co-workers (2011) have indicated that overexpression of miR-378 is 
associated with NSCLC brain metastasis by promoting cell migration, invasion and 
tumour angiogenesis, together with its potential use as a biomarker for characterizing 
NSCLC brain metastasis (Chen et al., 2011). The over-expression of miR-378 in A549-
I7 in this study was found to be in accordance with Chen et al., 2011, where lower 
protein expression of suppressor of fused homolog (SuFu) was detected in miR-378 
expressing A549 cells. TargetScan 5.2 algorithm suggested that SuFu encoding gene 
was a putative target of miR-378 with a context score of -0.14 [Appendix 9 (A)].  
 Among other miRNAs found to be down-regulated in A549-I7 including miR-
1827, miR-487b and miR-886-5p, all of which have been reported to play a role in 
cancer progression and metastasis (Liang et al., 2010; Gattolliat et al., 2011; Xiong et 
al., 2011). Attenuated interaction of miR-1827 with its 3’ UTR target gene L-MYC 
oncogene was reported to be more vulnerable to develop small cell lung cancer (SCLC) 
(Xiong et al., 2011). MiR-487b was significantly down-regulated in the high-risk 
neuroblastoma group and under-expression of miR-487b was proposed to be a 
biomarker of relapse among those classified as low-risk neuroblastoma patients 
(Gattolliat et al., 2011). Besides that, under-expression of miR-886-5p was reported in 
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aggressive ovarian cancer cells with high invasive and metastatic capacity (Liang et al., 
2010).  
 In this study, A549 was chosen to study the possible signalling pathways 
regulated by these 11 differentially expressed miRNA for lung cancer metastasis using 
pathway enrichment analyses to predict miRNA:target gene interactions. Taking into 
account that miRNAs suppress expression of targeted genes, as a result it should have 
an inverse correlation between the expression level of a given miRNA and the 
expression level of its putative targets (Ritchie et al., 2009). Based on past research 
works that reported gene expression during cancer metastasis, we included only 
expression of putative target genes that were inversely correlated with our miRNA 
expression to filtered out huge number of computationally predicted target genes from 
further analysis. Bioinformatics tools analysis together with literature surveys revealed 
the possible involvement of non-canonical Wnt/PCP, TGF-β, integrin-FAK-Src, MAPK 
and mTOR signalling as the key signalling pathways of these miRNAs in modulating 
A549 lung cancer metastasis.  
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5.1.1 Metastasis-Related MiRNAs in Relation To Wnt/PCP Signalling Pathway  
 Canonical Wnt pathway disruption leading to cancer progression was well 
documented in past research (Lee et al., 2008). Recently, an accumulating amount of 
research evidence have revealed the importance of the previously unacknowledged role 
of aberrant non-canonical Wnt/PCP signalling activation in human cancer progression 
such as abnormal tissue polarity, invasion, metastasis, and angiogenesis independent of 
the involvement of β-catenin (Lee et al., 2008; Wang et al., 2009).  
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Figure 5.1: Illustration of hypothetical Wnt/PCP signalling pathway as regulated by a 
list of significantly expressed miRNAs.  
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 According to DIANA-mirPath (MicroT-4.0) together with DIANA-microT 4.0 
and TargetScan 5.2 prediction algorithm, we postulated these miRNAs are targeting the 
components of non-canonical Wnt/PCP pathway in order to modulate invasion and 
migration of A549-I7. This study has provided some initial evidence of Wnt-related 
miRNAs that has yet to be reported (miR-576-3p, miR-629* and miR-1827) and were 
found to be down-regulated in invasive A549-I7 cells. Among the putative targets of 
these miRNAs are mRNAs encoding Wnt-5A, Fzd3 receptors, KITENIN, Dvl3 and 
Daam1, all of which are predicted to be up-regulated since they are putatively targeted 
by the down-regulated miRNAs. Targets of up-regulated Wnt-related miRNAs (miR-
671-5p, miR-92b and miR-550*) on the other hand, included mRNAs encoding for the 
two Wnt inhibitor of secreted frizzled-related proteins (sFRP) and prickle, which are 
both predicted to be down-regulated in A549-I7 cells (Figure 5.1). 
 Wnt-5A, Wnt-5B, and Wnt-11 are the non-canonical Wnt ligands transduce 
signals through it binding to Fzd3 or Fzd6 receptors to activate PCP pathway (Kotah, 
2005). Studies have reported the role of Wnt-5A promoting metastasis through Rac and 
JNK activation in melanoma, gastric cancer, and breast cancer (Weeraratna et al., 2002; 
Kurayoshi et al., 2006; Pukrop et al., 2006). In our study, we found that both miR-576-
3p and miR-1827 which targets Wnt-5A were down-regulated in A549-I7 when 
compared to A549-NI7. Down-regulation of both miRNAs and a predicted up-
regulation of Wnt-5A suggest that metastatic promotion might occur through non-
canonical Wnt/PCP pathway activation in NSCLC. 
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 sFRP is a negative regulator of Wnt signalling that prevents Wnt ligands from 
binding to Fzd receptor (Bhat et al., 2007). Lower expression of sFRP4 was observed in 
the more aggressive form of endometrial stromal sarcoma (Hrzenjak et al., 2004). 
Down-regulation of sFRP1 due to hypermethylation silencing of the associated 
promoter has been reported in NSCLC and mesothelioma (Lee et al., 2004; Fukui et al., 
2005). In this study, the mRNA encoding sFRP4 was predicted to be targeted by up-
regulated miR-671-5p, thus lower expression of sFRP4 was expected in A549-I7.  
 Past studies showed the three different Fzd (Fzd3, 6, and 7) are commonly up-
regulated in HCC cells. Suppression of Fzd7 by small-interfering RNA (siRNA) in 
colon cancer cells reduced invasion and motility activities through both canonical and 
non-canonical Wnt signalling pathway (Bengochea et al., 2008; Ueno et al., 2009). A 
series of research found higher expression of Vangl1 (Van Gogh, Drosophila)-like 1 
(VANGL1), renamed as KAI1 C-terminal interacting tetraspanin (KITENIN) in various 
metastatic lymph nodes and tissues. KITENIN play a potential role in promoting 
tumour invasion and metastasis by forming a functional complex with Dvl and PKCδ to 
modulate cell motility (Kho et al., 2008; Lee et al., 2009). Moreover, the metastasis-
promoting function of KITENIN was validated by Lee and coworkers (2005) where 
siRNA silenced the expression of KITENIN can inhibit colon cancer metastasis in mice 
model experiment. Fzd3 and KITENIN protein expression were predicted to be up-
regulated since their inhibitor regulators of miR-629*, miR-576-3p and miR-1827 were 
down-regulated in A549-I7, thus contribute to the invasion and metastatic capabilities 
of A549-I7.  
 
 
 
 
 98 
 
 Dvl homolog of Dvl-1, Dvl-2 and Dvl-3 are downstream effectors of Fzd 
receptors of PCP signalling. Significantly higher expression of Dvl-1 and Dvl-3 were 
reported in NSCLC clinical tumour specimens with nodal metastases and suppression of 
Dvl-1, -2 and -3 inhibits cell proliferation in human NSCLC cell lines (Uematsu et al., 
2003; Wang, 2009). Daam1, Profilin, RhoA/ROCK and Rac/JNK are also downstream 
effectors of PCP signalling that regulate cell movement via regulating stress fibers and 
actin cytoskeleton changes (Strutt et al., 1997; Habas et al., 2001; Habas et al., 2003; 
Katoh, 2005; Sato et al., 2006; Li et al., 2011). Dvl-dependent Wnt/PCP signals are 
transduced to RhoA signalling cascade through Daam1 and Daam2 (Kotah, 2005). The 
mRNA of Dvl-3 and Daam1 were not inhibited by its endogenous inhibitors of down-
regulated miR-629*, miR-576-3p and miR-1827 in A549-I7, allowing the expression of 
Dvl-3 and Daam1. Hence, activation of Wnt/PCP signalling pathway in A549-I7 was 
expected to transduce signals from Wnt ligands to the downstream effectors to activate 
profilin, RhoA/ROCK and Rac/JNK signalling cascade, that results in induction of actin 
cytoskeleton reorganization and cell movement of A549-I7 (Figure 5.1).  
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5.1.2 Metastasis-Related MiRNAs in Relation To TGF-β Signalling Pathway 
 TGF-β signalling pathway plays a biphasic role in tumour progression. TGF-β 
exerts anti-proliferative effects on normal epithelial cells and in early tumour 
development, but as tumours develop, they start to produce TGF-β, and TGF-β 
signalling promotes EMT, tumour invasiveness and metastases (Leivonen and Kähäri, 
2007; Jeon and Jen, 2010).  
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Figure 5.2: Illustration of hypothetical TGF-β signalling pathway as regulated by a list 
of significantly expressed miRNAs.  
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 TGF-β ligands expression activates TGF-β signalling pathway to promote 
tumour invasion and metastasis, while inhibition of TGF-β and TGF-β-RII has been 
shown to suppress cancer metastasis (Biswas et al., 2007; Leivonen and Kähäri, 2007; 
Xu et al., 2011). In Figure 5.2, we reported that the down-regulated miR-629*, miR-
576-3p and miR-1827 were predicted as endogenous inhibitors for both pro-metastatic 
proteins of TGF-β and TGF-β-RII. Therefore, activation of TGF-β signalling pathway 
was forecasted as the expression of pro-metastatic TGF-β and TGF-β-RII in A549-I7. 
 Past reports have also indicated that the inhibition of Smad3 or Smad2/3 in lung 
and breast cancer cell lines can lead to suppression of EMT and metastasis (Tian et al., 
2003; Reka et al., 2010). Smad2 and Smad3 of A549-I7 were predicted to be targets of 
the down-regulated miR-487b and miR-1827, which promote invasive and metastatic 
properties.  
 Inhibition of metastasis and tumourigenesis in breast and melanoma cancers 
were observed with overexpression of Smad7. This associated with up-regulation of E-
cadherin and down-regulation of MMP-2, MMP-9 and N-cadherin expression (Azuma 
et al., 2005; Javelaud et al., 2005). Smurf, an E3 ubiquitin ligase is another negative 
regulator of TGF-β signalling has been reported to work together with Smad7 to induce 
ubiquitination and degradation of Smad1, Smad2 and TGF-β family receptors (Ebisawa 
et al., 2001; Shi et al, 2004; Zhang et al., 2007). Xu and colleagues reviewed that 
activated Smads mediate transcriptional regulation through transcription factors of 
Snail, ZEB and bHLH family, resulting in repression of expression epithelial marker 
gene (e.g. E-cadherin) and activation of mesenchymal gene expression (e.g. N-cadherin, 
fibronectin, MMPs) during loss of cell-cell adherence (Xu et al., 2009). In this study, 
both negative regulators of TGF-β signalling, Smad7 and Smurf were predicted as the 
targets of three up-regulated miRNAs (miR-671-5p, miR-92b and miR-550*) in A549-
I7 cells. This prevented TGF-β receptor degradation and allows nuclear translocation of 
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Smad2/3, hence, regulating the expression of EMT-related targets such as MMPs and E-
cadherin proteins. E-cadherin is predicted as a target of three up-regulated miRNAs 
(miR-378, miR-671-5p and miR-92b) in A549-I7, thus further suppressing E-cadherin 
translation, resulting in the loss of cell-cell adhesion properties which might explain the 
observed weakened adhesion properties of A549-I7 during sub-culturing. 
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5.1.3 Metastasis-Related MiRNAs in Relation To Integrin Signalling Pathway 
 Tumour cell migration through tissue requires a combination of multiple cellular 
events where actin cytoskeleton is dynamically remodelled to produce the force 
necessary for cell migration (Pollard and Borisy, 2003). 
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Figure 5.3: Illustration of hypothetical integrin signalling pathway as regulated by a list 
of significantly expressed miRNAs.  
   
 103 
 
 The heterodimers transmembrane receptors of integrin (α and β) are 
fundamental for cell invasion and migration and has been implicated in the progression 
of cancer invasion and metastasis. For example, over-expression of integrin αvβ3 
heterodimers were reported in the more metastatic human melanoma cells and ectopic 
expression of αv or β3 integrin subunit able to increase metastatic potential of 
melanoma cell line (Gehlsen et al., 1992; Filardo et al., 1995; Neto et al., 2007). Also, 
past research found integrin β8 subunit plays a critical role in brain angiogenesis as 
ablation of this protein can interrupt brain blood vessel formation (Zhu et al., 2002). 
Target prediction analyses have predicted four down-regulated miRNAs (miR-629*, 
miR-487b, miR-886-5p and miR-1827) targeting mRNAs encoding heterodimeric trans-
membrane receptor integrin subunits (Figure 5.3). Up-regulation of integrin expression 
and clustering triggers downstream activation of integrin-FAK-Src intracellular 
signalling cascade in A549-I7 cells, encouraging cells to loosen their adhesion to the 
ECM and acquire a migratory and invasive phenotype (Hood and Cheresh, 2002). 
 The best characterized mammalian Rho GTPases are RhoA, Rac, and Cdc42 
which could regulate reorganization of the actin cytoskeleton to form stress fibers, 
lamellipodia, and filopodia, respectively (Nobes and Hall, 1995; Ridley, 2006). Rac1 
and Cdc42 activation depend on the ligation of integrins, whereas Rho is activated by 
integrins, syndecan-4 or other cell-surface receptors (Hood and Cheresh, 2002). 
Overexpression of RhoA, Rac1, and Cdc42 were associated with carcinogenesis and 
tumour progression (Fritz et al., 1999). Price and colleagues (1998) shown that 
activation of Rac and Cdc42 by intergin promoted cell spreading. β-p21-activated 
kinase-interacting exchange factor (β-Pix) is a guanine nucleotide exchange factor 
(GEF) for both GTPases of Rac1 and Cdc42 -targeting and -activating proteins. The 
binding of β-Pix with Rac1 to regulates membrane ruffles and focal adhesions for cell 
spreading (ten Klooster et al., 2006). Wiskott-Aldrich syndrome protein family 
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verprolin-homologous protein (WAVE) and Arp2/3 complex, are primary effectors of 
Rac1 for cell migration and invasion through actin polymerization to form lamellipodia 
protrusions at the leading edge that push the cell membrane forward (Takenawa and 
Miki, 2001; Suetsugu et al., 2002). Researchers reported WAVEs function as a 
metastasis-promoting protein downstream of Rac where knockdown of either WAVE2 
or WAVE3 resulted in significant decrease cell motility, migration and invasive 
properties (Kurisu et al, 2005; Sossey-Alaoui et al., 2007). Recently, Sossey-Alaoui and 
coworkers demonstrated an inverse correlation between WAVE3 and miRNAs of miR-
200 and miR-31 expression levels in invasive versus non-invasive cancer cells where 
miRNAs play a crucial role in cancer cell invasion by regulating WAVE3 expression 
leading to cytoskeleton remodeling (Sossey-Alaoui et al., 2009; Sossey-Alaoui et al., 
2011). In our study, β-pix was predicted to be a putative target of the down-regulated 
miR-1827 and therefore β-pix was expected to have an increased  expression and 
binding with Rac to mediate cell spreading in A549-I7. The down-regulated miR-1827 
and miR-576-3p were predicted to target the downstream targets of Rac1 (WAVE2, 
WAVE3 and Arp2/3), thus up-regulating the expression of WAVEs and Arp2/3. As a 
result, β-Pix together with WAVE complex and Arp2/3 promote the formation of 
lamellipodia in A549-I7 during cell migration. 
 The activation of p21-activated kinase (Pak) is one of the important downstream 
effector of Rac and Cdc42 to regulate cytoskeletal reorganization at the leading edge of 
migratory cells (Sells et al., 1997; Bokoch, 2003). Pak1 and pPak levels are increased in 
aggressive papillary thyroid cancers invasive fronts and the activity of PAK has been 
linked to regulate tumour invasiveness and motility of various human cancer cell lines 
(Kumar et al., 2006; McCarty et al., 2010). Pak as well as Rho, Rac, Cdc42,
 
and ROCK 
can then trans-phosphorylate
 
and activate LIM kinase (LIMK) (Bernard, 2007). Several 
reports indicate LIMK promotes cell invasion in vitro where higher LIMK expression 
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level in invasive prostate and breast cancer cell lines in comparison with less invasive 
cells were observed (Davila et al., 2003; Yoshioka et al., 2003). In vivo studies showed 
increased in LIMK induces tumour metastases (Bagheri-Yarmand et al., 2006). MiR-
629*, miR-487b, miR-576-3p, and miR-1827 were predicted to target Pak1, Pak6, Pak7 
and LIMK1 and their expression are expected to be up-regulated in A549-I7 to promote 
signal transduction cascade for actin polymerization. 
 On the other hand, studies showed that Cdc42 activates Neural Wiskott-Aldrich 
syndrome protein (N-WASP), a WASP members of nucleation proteins, forms a 
complex with Arp2/3 in promoting actin polymerization, filopodia formation, cell 
motility, and invasion (Lorenz et al., 2004; Yamaguchi et al., 2005). Both miR-629* 
and miR-1827 were predicted to target mRNA encoding Cdc42, β-pix and Arp2/3 
complex. Therefore, β-pix, Cdc42 and Arp2/3 complex were supposed to over-express 
in A549-I7 and lead to the formation of filopodia that facilitate cancer migration.  
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5.1.4 Metastasis-Related MiRNAs in Relation To MAPK and mTOR Signalling 
Pathways 
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Figure 5.4: Illustration of hypothetical MAPK and mTOR signalling pathways as 
regulated by a list of significantly expressed miRNAs.  
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 Past reports have shown that integrin together with FAK cross-talk with other 
signalling pathways to promote cancer cell migration, invasion and metastasis (Eliceiri, 
2001). Integrin binding can induce FAK auto-phosphorylation and creates a binding site 
to recruit Src family kinases (SFKs), the largest of the non-receptor-tyrosine-kinase. 
Additionally, SFK can also phosphorylate additional sites in FAK, leading to the 
recruitment of the Grb2 adaptor molecule, which in turn activates multiple downstream 
signalling pathways including the MAPK pathway (Schlaepfer et al., 1994; Guo et al., 
2004). In our study, down-regulated miR-1827 and miR-629* were predicted to target 
Grb-2 and MAPK expression respectively, thus activating the MAPK pathway which 
functions to promote myosin light-chain kinase (MLCK) phosphorylation and enhance 
cell migration, which was consistent with the aggressive invasion and migration 
properties of A549-I7 (Figure 5.4) (Klemke et al., 1997; Schlaepfer et al., 1998).  
 Besides the MAPK pathway, Meng and colleagues (2009) also demonstrated 
FAK cross-talks with Src to regulate the PI3K/AKT pathway to promote A549 lung 
cancer cells migration and invasion (Meng et al., 2009). PI3K was predicted to be 
targeted by miR-629*, miR-576-3p, miR-886-5p and miR-487b and thus up-regulation 
of PI3K was predicted to occur in A549-I7. Finally, the hypoxia-inducible factor 1α 
(HIF-1α) which is a downstream target of the mTOR pathway cascade, was also 
deduced as a putative target of miR-576-3p (Figure 5.4). An uninhibited expression of 
HIF-1α was predicted which consequently leads to the activation of VEGF expression, a 
commonly known potent mediator of angiogenesis (reviewed by Karar and Maity, 
2009). 
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 In this study, only miRNAs that have inverse correlation expression level with 
their predicted targets that reported in past research were included in the hypothetical 
signalling network in Figure 4.32. miRNAs that have contradictory expression level 
with their putative targets DIANA-microT 4.0 and TargetScan 5.2 were omitted from 
the hypothetical pathway. For example, TargetScan 5.2 predicted both down-regulated 
miR-1827 with context score of -0.17 and up-regulated miR-671-5p with context score 
of -0.21 are targeting mRNA encoding Pak6 protein. Also, WAVE2 was the putative 
target of both miR-1827 with context score of -0.36 and miR-671-5p with context score 
of -0.10 [Appendix 9 (A)]. Since both Pak6 and WAVE2 were reported to be up-
regulated in highly metastatic cells, hence only down-regulated miR-1827 was included 
into the hypothetical pathway regardless of the context score. Also, an up-regulated 
miR-671-5p (with miTG score of 0.377) and 2 down-regulated miRNAs of miR-576-3p 
(with miTG score of 0.214) and miR-1827 (with miTG score of 0.445) are predicted 
targeting mRNA encoding TGF-β-RII according to DIANA-microT 4.0 algorithm 
[Appendix 9 (B)]. Here, only miR-576-3p and miR-1827 were included in the 
hypothetical signalling network since up-regulation of TGF-βII was reported in 
aggressive cells.  
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5.2 Future Perspectives 
 Our results provide novel insights of these metastasis-related miRNAs work in 
concert to regulate signalling network for cancer metastasis. Target and pathway 
prediction analyses are helpful to narrow down targets and pathways. Based on this 
hypothetical signalling network, we can later select candidate miRNAs for further 
investigation and refine the miRNA functions via functional experiments.  
 Prior to functional studies, a few other popular target prediction algorithms such 
as miRanda and PicTar can be employed to further filter out the list of putative targets 
of candidate miRNAs from the proposed hypothetical signalling network. First, the 
expression of the selected candidate miRNAs will need to examine their expression 
pattern in lung cancer patients using Real-Time PCR analysis on clinical metastatic 
tumour tissues with normal tissues. Luciferase assay will be performed to examine 
whether a predicted target gene by target prediction algorithms is a functional target of 
candidate miRNA. Over-expression or inhibition of endogenous miRNAs by 
transfecting sub-cell lines with mimics and antagomiRs will be performed in order to 
examine if changing endogenous miRNA expression can change the abilities of 
invasion and migration. Real-Time PCR will then be performed to detect mature 
putative miRNA expression of transfected-cells to monitor transfection efficiency. Soon 
after, transwell invason assay, wound healing assay and cell proliferation assay will be 
performed to assess invasion, migration and proliferation properties of cells transfected 
with the candidate miRNA between non-transfected cells. Western blotting will be 
performed to detect the proteins expression of putative target genes of a candidate 
miRNAs. 
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 Pathway enrichment analysis predicted the involvement of miR-1827 in all three 
major pathways of Wnt/PCP, TGF-β and integrin-Fak-Src signalling. Also, miRNA 
microarray revealed miR-1827 was found to be differentially under-expressed in 
MCF7-I7. Taken together, it is interesting to investigate the function of miR-1827 
among all down-regulated miRNAs as a candidate miRNA to perform functional study. 
However, miR-1827 was the lowest expression among the 4 validated miRNAs as it 
needed 30 ng as a starting material to perform Real-Time PCR in this study. This 
phenomenon can be explain when a slight decrease of the endogenous miR-1827 
expression in cells can drastically change actin cytoskeleton distribution as well as 
activate EMT to gain metastatic properties.  
 On the other hand, miR-487b is another potential anti-metastatic miRNAs for 
both lung and prostate cancer where miRNA microarray also revealed miR-487b 
expression was down-regulated in PC-3-I7. According to pathway enrichment analysis, 
miR-487b mainly targeting TGF-β and integrin signalling cascade in regulate EMT and 
actin polymerization. Therefore, it is interested to find out the actual functional role of 
miR-487b in lung and prostate cancer invasion and migration by carried out functional 
studies in future. 
 The miRNA* of miR-629* was also shown to be a potential anti-metastatic 
miRNA according to pathway enrichment analysis. MiR-629* expression has the 
highest fold change among down-regulated miRNAs. Pathway enrichment analysis 
revealed miR-629* might potentially act on all three major signalling pathways of non-
canonical Wnt/PCP, TGF-β and integrin signalling cascades predicted by algorithm to 
regulate actin polymerization and cell motility. Thus, miR-629* is another potential 
candidate miRNA to perform further studies on. 
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 Among the up-regulated miRNAs, miR-92b was found to be most potential pro-
metastatic miRNAs as it was predicted to targeting many important molecule 
components of TGF-β and non-canonical Wnt/PCP signalling pathways. Thus, miR-92b 
is a potential candidate of up-regulated miRNA to perform functional studies in future. 
 MiR-25* and miR-106b* are among 11 differentially expressed miRNAs that do 
not have any putative targets in the hypothetical signalling network of Figure 4.32. This 
two miRNAs can be omitted from functional studies in future since both TargetScan 5.2 
and DIANA-microT 4.0 did not predicted both miR-25* and miR-106b* in the 
proposed hypothetical signalling network.  
 Besides studying the mechanism of miRNAs in regulating cancer invasion and 
migration, the establishment of high and low invasiveness sub-cell lines also provides 
an excellent platform to investigate the other molecular aspects of migration and 
invasion in lung, breast and prostate cancer. Also, miRNAs microarray expression 
validation will need to perform on the differentially expressed miRNAs of PC-3 and 
MCF7 using Real-Time PCR in future. Later, pathway enrichment analysis, candidate 
miRNAs selection and functional studies will be performed on PC-3 and MCF7 
respectively. 
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CHAPTER 6: CONCLUSION 
 
 
 In this study, we have identified a list of differentially expressed miRNAs 
between high and low invasiveness sub-cell lines of A549, PC-3 and MCF7. A 
hypothetical pathway network was proposed for A549 lung adenocarcinoma cell line, 
which provided novel insights of how these metastasis-related miRNAs work in concert 
to regulate the metastasis signalling network for lung cancer metastasis. Overall, data in 
this study provided valuable information not only with regards to the development of 
therapies involving miRNA control elements to stop tumor invasion and metastasis, but 
also for the development of potential candidate metastatic markers for lung cancer 
classification and prognosis as well. Pathway enrichment analysis was helpful to narrow 
down putative targets and pathways, and candidate miRNAs can be selected for further 
studies of experiments verifications to investigate the mechanism of miRNAs with its 
downstream targets in contribution to A549 lung cancer invasion and metastasis 
particularly in pathways such as the TGF-β, non-canonical Wnt/PCP and integrin-FAK-
Src intracellular signalling cascade. 
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APPENDICES 
 
Appendix 1: Solutions and Formulations 
Appendix 1.1: Cell Culture 
(A) Culture Media 
To prepare 250.0 ml of complete Dulbeco’s Modified Eagle Medium (DMEM) 
culture media supplemented with 10.0 % (v/v) fetal bovine serum (FBS) (JR Scientific 
Inc, USA), 25.0 ml of FBS was added into a sterile autoclaved bottle and mixed with 
225.0 ml of sterile DMEM (Thermo Scientific Hyclone, USA), then was stored at 4ºC. 
Same procedure for Roswell Park Memorial Institute 1640 (RPMI 1640) (Thermo 
Scientific Hyclone, USA) supplemented with 10.0 % (v/v) FBS. Culture media were 
also supplemented with 100.0 U/ml penicillin and 100.0 μg/ml streptomycin (Lonza, 
USA). 
 
(B) 1X PBS 
1.0 L of 1X concentration of Phosphate Buffered Saline (PBS) solution with pH 
at 7.4 was prepared by mixing 100.0 ml of pre-mixed 10X calcium- and magnesium-
free PBS (Mediatech Cellgro®, USA) with pH 7.4 and topped up with distilled water to 
1.0 L. The 1X PBS was autoclaved at 121ºC, 15 psi for 15 min and stored at room 
temperature. 
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(C) 0.1 % (v/v) Trypsin-0.53 mM EDTA 
98.0 mg of ethylenediaminetetraacetic acid (EDTA) (GibcoBRL, USA) was 
dissolved in 500.0 ml of 1X PBS to prepare 1X PBS-0.53 mM EDTA, followed by 
sterile autoclaved at 121ºC, 15 psi for 15 min and was stored at room temperature. 
100.0 ml of 0.1% (v/v) of trypsin solution was prepared by mixing 4.0 ml of 2.5% (v/v) 
trypsin-EDTA (Sigma-Aldrich, USA) with 96.0 ml of sterile 1X PBS-0.53 mM EDTA 
and was stored at room temperature. 
 
(D) 0.04 % (w/v) Trypan Blue Dye 
 10.0 ml of 0.04 % (w/v) of trypan blue solution was prepared by dissolving 4.0 
mg of trypan blue (Sigma-Aldrich, USA) in 10.0 ml of 1X PBS, incubated at 60ºC to 
ensure complete dissolving. The solution was then stored at room temperature.  
 
Appendix 1.2: Transwell Invasion Assay 
(A) Matrigel 
Stock Matrigel (BD Biosciences, USA) was thawed on ice at 4ºC overnight. To 
prepare 1.5 mg/ml of Matrigel, 100.0 μl of 8.9 mg/ml of Matrigel (from lot number: 
A0952) was diluted with 593.0 μl of cold serum free media on ice. Diluted Matrigel was 
stored at -20ºC.  
 
(B) 1.0 % (w/v) Methylene Blue 
100.0 ml of 1.0 % (w/v) of Methylene blue was prepared by dissolving 1.0 g of 
methylene blue powder (Sigma, USA) in distilled water, incubated at 60ºC to ensure 
complete dissolving. The solution was then stored at room temperature.  
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Appendix 1.3: Wound Healing Assay 
(A) Mitomycin C Stock Solution 
Stock solution of 1.0 mg/ml of mitomycin C was prepared by mixing 2.0 mg of 
Mitomycin C, Streptomyces caespitosus (Merck Calbiochem
®
, Germany) with 20.0 ml 
of sterile 1X PBS and sterile filtered using 0.45 μm syringe filter (Sartorius, USA). The 
dissolved stock solution was then aliquoted and freeze at -20ºC up to 3 months and 
protected from light.    
 
Appendix 1.4: MiRNA Microarray  
(A) DEPC-Treated Water 
 1.0 L of 0.1 % (v/v) diethy pyrocarbonate (DEPC)-treated water was prepared 
by adding 1.0 ml of DEPC (Merck, Germany) to 1.0 L of distilled water. The solution 
was mixed well by shaking and left at room temperature for overnight prior to being 
autoclaved at 121ºC, 15 psi for 15 min and was stored at room temperature.  
 
(B) 1.0 mM Tris Solution 
 50.0 ml nuclease-free water (Qiagen, Germany) was transferred to a 50.0 ml 
DEPC-treated bottle. 50.0 μl of nuclease-free water was discarded and 50.0 μl of 1 M 
Tris-HCl, pH 8 (Ambion, USA) was added without adjusting pH reading. The diluted 
1.0 mM Tris solution was stored at room temperature up to 3 months. 
 
(C) 1X PBS, 0.02 % (v/v) Tween-20 
 100.0 ml of 10X PBS pH 7.4 and 0.2 ml Tween-20 (Promega, USA) were added 
into a 1.0 L bottle, then was topped up with distilled water to 1.0 L. The solution was 
kept at room temperature up to 3 months. 
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(D) 5 % (w/v) BSA  
 2.0 g powdered bovine serum albumin (BSA) (Merck Calbiochem
®
, Germany) 
was dissolved with 40.0 μl of 1X PBS in a 50.0 ml conical tube by vortex to mix. 8 
aliquots of 5.0 ml of 5.0 % BSA was made and stored at -20ºC up to 6 months. An 
aliquot can be stored at 4ºC for a week once thawed and do not freeze/thaw more than 4 
times. 
 
(E) 5X SSC, 0.05 % (v/v) SDS, 0.005 % (v/v) BSA 
 2.5 ml of 20X SSC (Applied Biosystems, USA), 0.05 ml 10.0 % (v/v) sodium 
dodecyl sulfate polyacrylamide (SDS) (Applied Biosystems, USA) and 0.01 ml of 5.0 
% (w/v) BSA in 1X PBS were added together with water to a final volume of 10.0 ml. 
10.0 ml of the mixture was aliquoted and each aliquot was stored at -20ºC up to 6 
months. An aliquot can be stored at 4ºC for a week once thawed with not freeze/thaw 
more than 4 times. 
 
Appendix 2: Commercial Kits 
Commercial kits used in this study were: 
1. Qiagen miRNeasy mini kit (Qiagen, Germany) 
2. Agilent RNA 6000 Nano Kit (Agilent Technologies, USA) 
3. FlashTag™ Biotin RNA Labelling Kit for Affymetrix® GeneChip® miRNA Arrays 
(Genisphere, USA) 
4. GeneChip® miRNA Array (Affymetrix, USA) 
5. TaqMan® microRNA assay (Applied Biosystems, USA) 
6. TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, USA)  
7. TaqMan® Fast Advanced Master Mix Product (Applied Biosystems, USA) 
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Appendix 3: Transwell Invasion Assay Data 
 
(A) A549 Transwell Invasion Assay Data 
Sub-cell 
lines 
Invaded cells per field 
Replicates 
Average Std dev SEM 
1 2 3 
A549-I7 68 38 74 60 19.3 11.14 
A549-NI7 15 15 32 21 9.8 5.67 
 
 
(B) PC-3 Transwell Invasion Assay Data   
Sub-cell 
lines 
Invaded cells per field 
Replicates 
Average  Std dev SEM 
1 2 3 
PC-3-I7 90 99 80 90 9.5 5.49 
PC-3-NI7 38 14 27 26 12.0 6.94 
 
 
(C) MCF7 Transwell Invasion Assay Data 
Sub-cell 
lines 
Invaded cells per field 
Replicates 
Average Std dev SEM 
1 2 3 
MCF7-I7 63 115 80 86 26.5 15.31 
MCF7-NI7 24 31 32 29 4.4 2.52 
 
 
(D) MDA-MB-231 Transwell Invasion Assay Data 
Sub-cell lines 
Invaded cells per field 
Replicates 
Average Std dev SEM 
1 2 3 
MDA-MB-231-I7 40 105 98 81 35.7 20.60 
MDA-MB-231-NI7 19 25 28 24 4.6 2.65 
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Appendix 4: Wound Healing Assay Data 
 
(A) A549 Wound Healing Assay Data  
Sample 
Replicate 
Average Std Dev SEM 
1 2 3 4 
Open image area of A549-I7 0 h 0.3604 0.4832 0.4809 0.4324 
   Open image area of A549-I7 28 h 0.0830 0.1816 0.2494 0.1761 
Area migrated of A549-I7 0.2774 0.3015 0.2314 0.2564 
Wound healing of A549-I7 (%) 77.0 62.4 48.1 59.3 61.7 14.42 7.211 
Open image area of A549-NI7 0 h 0.3876 0.4930 0.5044 0.5330 
   Open image area of A549-NI7 28 h 0.2436 0.4222 0.3808 0.4715 
Area migrated by A549-NI7 0.1440 0.0708 0.1237 0.0615 
Wound healing of A549-NI7 (%) 37.2 14.4 24.5 11.5 21.9 11.42 5.710 
 
 
 
(B) PC-3 Wound Healing Assay Data 
Sample 
Replicate 
Average Std Dev SEM 
1 2 3 4 
Open image area of PC-3-I7 0 h 0.3855 0.4095 0.4754 0.3554 
   Open image area of PC-3-I7 28 h 0.2363 0.1412 0.1657 0.0577 
Area migrated of PC-3-I7 0.1492 0.2683 0.3098 0.2978 
Wound healing of PC-3-I7 (%) 38.7 65.5 65.2 83.8 63.3 15.38 7.69 
Open image area of PC-3-NI7 0 h 0.4005 0.4837 0.4292 0.2986 
   Open image area of PC-3-NI7 28 h 0.3195 0.3173 0.2933 0.1408 
Area migrated by PC-3-NI7 0.0810 0.1664 0.1359 0.1577 
Wound healing of PC-3-NI7 (%) 20.2 34.4 31.7 52.8 34.8 7.52 3.76 
 
 
 135 
 
(C) MCF7 Wound Healing Assay Data  
Sample 
Replicate 
Average Std Dev SEM 
1 2 3 4 
Open image area of MCF7-I7 0 h 0.3298 0.3928 0.4050 0.3377 
   Open image area of MCF7-I7 23 h 0.0284 0.1100 0.0899 0.0000 
Area migrated by MCF7-I7 0.3014 0.2828 0.3151 0.3377 
Wound healing of MCF7-I7 (%) 91.4 72.0 77.8 100.0 85.3 9.95 4.977 
Open image area of MCF7-NI7 0 h 0.3318 0.3999 0.3808 0.3887 
   Open image area of MCF7-NI7 23 h 0.1967 0.2078 0.2408 0.1975 
Area migrated by MCF7-NI7 0.1351 0.1921 0.1400 0.1912 
Wound healing of MCF7-NI7 (%) 40.7 48.0 36.8 49.2 43.7 5.72 2.860 
 
 
(D) MDA-MB-231 Wound Healing Assay  
Sample 
Replicate 
Average Std Dev SEM 
1 2 3 4 
Open image area of MDA-MB-231-I7 0 h 0.4174 0.5239 0.5478 0.4878 
   Open image area of MDA-MB-231-I7 28 h 0.2726 0.2365 0.2198 0.2777 
Area migrated by MDA-MB-231-I7 0.1447 0.2874 0.3279 0.2101 
Wound healing of MDA-MB-231-I7 (%) 34.7 54.9 59.9 43.1 48.1 13.34 6.668 
Open image area of MDA-MB-231-NI7 0 h 0.4399 0.5459 0.5642 0.5459 
   Open image area of MDA-MB-231-NI7 28 h 0.3689 0.3614 0.4396 0.3399 
Area migrated by MDA-MB-231-NI7 0.0709 0.1845 0.1246 0.2060 
Wound healing of MDA-MB-231-NI7 (%) 16.1 33.8 22.1 37.7 27.4 8.99 4.494 
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Appendix 5: Cell Proliferation Assay Data 
Appendix 5.1: Number of Viable Cells Data 
 
(A) Number of Viable Cells Data of A549  
Day 
number of viable cells (x 1,000) 
A549-I7 A549-NI7 A549 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
1 2 3 1 2 3 1 2 3 
0 20 20 20 20 - - 20 20 20 20 - - 20 20 20 20 - - 
1 35 40 40 38 2.9 1.67 30 40 40 37 5.8 3.33 30 50 50 43 11.5 6.67 
2 100 80 80 87 11.5 6.67 110 80 100 97 15.3 8.82 100 120 90 103 15.3 8.82 
3 500 220 250 323 153.7 88.76 420 360 310 363 55.1 31.80 570 200 180 317 219.6 126.80 
4 670 800 520 663 140.1 80.90 660 840 860 787 110.2 63.60 630 800 740 723 86.2 49.78 
5 1150 900 1360 1137 230.3 132.96 910 1560 1800 1423 460.5 265.85 1450 1100 1350 1300 180.3 104.08 
6 1550 1440 1720 1570 141.1 81.45 1110 1680 1780 1523 361.4 208.67 1670 1480 1890 1680 205.2 118.46 
7 2420 1930 2210 2187 245.8 141.93 2200 2480 2200 2293 161.7 93.33 1920 2190 2020 2043 136.5 78.81 
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(B) Number of Viable Cells Data of PC-3 
Day 
number of viable cells (x 1,000) 
PC-3-I7 PC-3-NI7 PC-3 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
1 2 3 1 2 3 1 2 3 
0 20 20 20 20 - - 20 20 20 20 - - 20 20 20 20 - - 
1 50 70 40 53 15.3 8.82 60 40 40 47 11.5 6.67 40 50 40 43 5.8 3.33 
2 80 100 110 97 15.3 8.82 60 90 110 87 25.2 14.53 98 130 90 106 21.2 12.22 
3 420 380 310 370 55.7 32.15 210 360 260 277 76.4 44.10 380 480 530 463 76.4 44.10 
4 950 1180 1220 1117 145.7 84.13 800 600 830 743 40.4 23.33 1080 820 830 910 147.3 85.05 
5 1560 1830 1360 1583 235.9 136.18 1120 1560 1630 1437 276.5 159.62 1450 2000 1820 1757 280.4 161.90 
6 2100 2400 2210 2237 151.8 87.62 2380 2590 1960 2310 320.8 185.20 2300 2410 2140 2283 135.8 78.39 
7 2990 2500 2850 2780 252.4 145.72 2610 2460 2840 2637 191.4 110.50 3100 2740 2230 2690 437.1 252.39 
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(C) Number of Viable Cells Data of MCF7 
Day 
number of viable cells (x 1,000) 
MCF7-I7 MCF7-NI7 MCF7 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
1 2 3 1 2 3 1 2 3 
0 20 20 20 20 - - 20 20 20 20 - - 20 20 20 20 - - 
1 30 30 40 33 5.8 3.33 20 40 40 33 11.5 6.67 30 20 40 30 10.0 5.77 
2 130 100 110 113 15.3 8.82 70 110 70 83 23.1 13.33 160 180 130 157 25.2 14.53 
3 490 380 270 380 110.0 63.51 380 360 240 327 75.7 43.72 450 390 460 433 37.9 21.86 
4 900 1360 1220 1160 235.8 136.14 790 920 1100 937 155.7 89.88 1210 906 778 965 221.9 128.11 
5 1960 1730 1970 1887 135.8 78.39 1740 1560 1630 1643 90.7 52.39 1840 2010 1820 1890 104.4 60.28 
6 2230 2400 2210 2280 104.4 60.28 2150 2010 1980 2047 90.7 52.39 2370 1970 2190 2177 200.3 115.66 
7 2580 2800 2450 2610 176.9 102.14 2320 2330 2630 2427 176.2 101.71 2500 2470 2810 2593 188.2 108.68 
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(D) Number of Viable Cells Data of MDA-MB-231 
Day 
number of viable cells (x 1,000) 
MDA-MB-231-I7 MDA-MB-231-NI7 MDA-MB-231 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
Replicate 
Avg 
Std 
Dev 
SEM 
1 2 3 1 2 3 1 2 3 
0 20 20 20 20 - - 20 20 20 20 - - 20 20 20 20 - - 
1 50 30 40 40 10.0 5.77 40 20 30 30 10.0 5.77 30 20 20 23 5.8 3.33 
2 50 100 70 73 25.2 14.53 90 110 60 87 25.2 14.53 90 120 130 113 20.8 12.02 
3 190 300 270 253 56.9 32.83 200 360 240 267 83.3 48.07 450 390 460 433 37.9 21.86 
4 800 550 770 707 136.5 78.81 460 920 1110 830 334.2 192.96 1010 860 790 887 112.4 64.89 
5 1330 990 1,540 1287 277.5 160.24 820 1410 1680 1303 439.8 253.92 1340 1480 1610 1477 135.0 77.96 
6 1830 1640 1440 1637 195.0 112.60 1330 2010 1980 1773 384.2 221.84 2170 1860 2000 2010 155.2 89.63 
7 2150 1840 2350 2113 257.0 148.36 2430 2330 1990 2250 230.7 133.17 2550 2210 1970 2243 291.4 168.26 
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Appendix 5.2: Doubling Time Data  
 
(A) A549 Doubling Time Data 
Day 4 
A549-I7 A549-NI7 A549 
Replicate 
Average 
Replicate 
Average 
Replicate 
Average 
1 2 3 1 2 3 1 2 3 
number of viable cells (x1,000) 670 800 520 663 660 840 860 787 630 800 740 723 
Ratio 33.5 40.0 26.0 33.2 33.0 42.0 43.0 39.3 31.5 40.0 37.0 36.2 
Doubling time (days) 0.79 0.75 0.85 0.79 0.79 0.74 0.74 0.76 0.80 0.75 0.77 0.77 
Doubling time (h) 18.9 18.0 20.4 19.0 19.0 17.8 17.7 18.1 19.3 18.0 18.4 18.5 
Std Dev 1.20 0.74 0.64 
SEM of doubling time (h) 0.695 0.429 0.369 
 
 
(B) PC-3 Doubling Time Data  
Day 4 
PC-3-I7 PC-3-NI7 PC-3 
Replicate 
Average 
Replicate 
Average 
Replicate 
Average 
1 2 3 1 2 3 1 2 3 
number of viable cells (x1,000) 950 1180 1220 840 800 600 830 743 1080 820 830 910 
Ratio 47.5 59.0 61.0 42.0 40.0 30.0 41.5 37.2 54.0 41.0 41.5 45.5 
Doubling time (days) 0.72 0.68 0.67 0.74 0.75 0.82 0.74 0.77 0.70 0.75 0.74 0.73 
Doubling time (h) 17.2 16.3 16.2 17.8 18.0 19.6 17.9 18.4 16.7 17.9 17.9 17.4 
Std Dev (h) 0.57 0.94 0.70 
SEM of doubling time (h) 0.330 0.541 0.403 
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 (C) MCF7 Doubling Time Data  
 
Day 4 
MCF7-I7 MCF7-NI7 MCF7 
Replicate 
Average 
Replicate 
Average 
Replicate 
Average 
1 2 3 1 2 3 1 2 3 
number of viable cells (x1,000) 900 1360 1220 1160 790 920 1100 937 1210 906 778 965 
Ratio 45.0 68.0 61.0 58.0 39.5 46.0 55.0 46.8 60.5 45.3 38.9 48.5 
Doubling time (days) 0.73 0.66 0.67 0.68 0.75 0.72 0.69 0.72 0.68 0.73 0.76 0.72 
Doubling time (h) 17.5 15.8 16.2 16.4 18.1 17.4 16.6 17.3 16.2 17.4 18.2 17.2 
Std Dev (h) 0.89 0.75 0.99 
SEM of doubling time (h) 0.515 0.432 0.571 
 
 
(D) MDA-MB-231 Doubling Time Data 
Day 4 
MDA-MB-231-I7 MDA-MB-231-NI7 MDA-MB-231 
Replicate 
Avergage 
Replicate  
Average 
Replicate 
Average 
1 2 3 1 2 3 1 2 3 
number of viable cells (x1,000) 800 550 770 840 460 920 1110 830 1010 860 790 887 
Ratio 40.0 27.5 38.5 42.0 23.0 46.0 55.5 41.5 50.5 43.0 39.5 44.3 
Doubling time (days) 0.75 0.84 0.76 0.74 0.88 0.72 0.69 0.74 0.71 0.74 0.75 0.73 
Doubling time (h) 18.0 20.1 18.2 17.8 21.2 17.4 16.6 17.9 17.0 17.7 18.1 17.5 
Std Dev (h) 1.13 2.49 0.57 
SEM of doubling time (h) 0.651 1.435 0.332 
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Appendix 6: Agilent Bioanalyzer Data 
 
Sub-cell line Replicate 
RNA 
concentration 
(ng/μl) 
28S/18S rRNA 
Ratio 
RNA area 
PC-3-I7 
 
1 518 2.3 92.1 
2 501 2.3 89.2 
3 367 2.1 63.5 
4 446 2.3 79.4 
PC-3-NI7 
 
1 1132 2.0 201.3 
2 1220 2.0 217.0 
3 1322 2.1 235.1 
4 1240 1.7 220.6 
A549-I7 
1 588 2.1 104.5 
2 559 2.1 99.4 
3 611 2.1 108.7 
4 643 2.1 114.3 
A549-NI7 
1 919 1.7 428.2 
2 1023 2.0 476.7 
3 740 2.0 345.0 
4 1053 2.0 490.6 
MCF7-I7 
 
1 1053 2.1 490.8 
2 1215 1.9 566.5 
3 1406 2.2 655.2 
4 1077 2.2 501.8 
MCF7-NI7 
1 1110 2.1 517.5 
2 1095 2.2 510.5 
3 977 2.2 455.5 
4 1091 2.1 508.5 
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Appendix 7: MiRNA Microarray Data 
 
(A) A549 MiRNA Microarray Data 
miRNA 
Mature miRNA 
ID 
miRBase 
Accession Number 
Sequence 
miR-378 hsa-miR-378a-3p MIMAT0000732 
ACUGGACUUGGAGU
CAGAAGG 
miR-671-5p hsa-miR-671-5p MIMAT0003880 
AGGAAGCCCUGGAG
GGGCUGGAG 
miR-25* hsa-miR-25-5p MIMAT0004498 
AGGCGGAGACUUGG
GCAAUUG 
miR-92b hsa-miR-92b-3p MIMAT0003218 
UAUUGCACUCGUCC
CGGCCUCC 
miR-106b* hsa-miR-106b-3p MIMAT0004672 
CCGCACUGUGGGUA
CUUGCUGC 
miR-550* hsa-miR-550a-3p MIMAT0003257 
UGUCUUACUCCCUC
AGGCACAU 
miR-629* hsa-miR-629-3p MIMAT0003298 
GUUCUCCCAACGUA
AGCCCAGC 
miR-576-3p hsa-miR-576-3p MIMAT0004796 
AAGAUGUGGAAAAA
UUGGAAUC 
miR-886 hsa-miR-886 MI0005527 
CGGGUCGGAGUUAG
CUCAAGCGG 
miR-487b hsa-miR-487b MIMAT0003180 
AAUCGUACAGGGUC
AUCCACUU 
miR-1827 hsa-miR-1827 MIMAT0006767 
UGAGGCAGUAGAUU
GAAU 
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(B) PC3 MicroRNA Microarray Data 
miRNA 
Mature miRNA 
ID 
miRBase 
Accession Number 
Sequence 
miR-129-1* hsa-miR-129-1-3p MIMAT0004548 
AAGCCCUUACCCCA
AAAAGUAU 
miR-606 hsa-miR-606 MIMAT0003274 
AAACUACUGAAAAU
CAAAGAU 
miR-34b* hsa-miR-34b-5p MIMAT0000685 
UAGGCAGUGUCAUU
AGCUGAUUG 
miR-19b-1 hsa-miR-19b-3p MIMAT0000074 
UGUGCAAAUCCAUG
CAAAACUGA 
miR-320a hsa-miR-320a MIMAT0000510 
AAAAGCUGGGUUGA
GAGGGCGA 
miR-132* hsa-miR-132-5p MIMAT0004594 
ACCGUGGCUUUCGA
UUGUUACU 
miR-744 hsa-miR-744-5p MIMAT0004945 
UGCGGGGCUAGGGC
UAACAGCA 
miR-654 hsa-miR-654-5p MIMAT0003330 
UGGUGGGCCGCAGA
ACAUGUGC 
miR-409 hsa-miR-409-5p MIMAT0001638 
AGGUUACCCGAGCA
ACUUUGCAU 
miR-1180 hsa-miR-1180 MIMAT0005825 
UUUCCGGCUCGCGU
GGGUGUGU 
miR-503 hsa-miR-503 MIMAT0002874 
UAGCAGCGGGAACA
GUUCUGCAG 
miR-423 hsa-miR-423-5p MIMAT0004748 
UGAGGGGCAGAGAG
CGAGACUUU 
miR-382 hsa-miR-382 MIMAT0000737 
GAAGUUGUUCGUGG
UGGAUUCG 
miR-487b hsa-miR-487b MIMAT0003180 
AAUCGUACAGGGUC
AUCCACUU 
miR-409 hsa-miR-409-3p MIMAT0001639 
GAAUGUUGCUCGGU
GAACCCCU 
miR-210 hsa-miR-210 MIMAT0000267 
CUGUGCGUGUGACA
GCGGCUGA 
miR-342 hsa-miR-342-3p MIMAT0000753 
UCUCACACAGAAAU
CGCACCCGU 
miR-134 hsa-miR-134 MIMAT0000447 
UGUGACUGGUUGAC
CAGAGGGG 
miR-379 hsa-miR-379-5p MIMAT0000733 
UGGUAGACUAUGGA
ACGUAGG 
miR-708 hsa-miR-708-5p MIMAT0004926 
AAGGAGCUUACAAU
CUAGCUGGG 
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(C) MCF7 MicroRNA Microarray Data 
miRNA 
Mature 
miRNA ID 
miRBase 
Accession 
Number 
Sequence 
miR-302c* 
hsa-miR-302c-
5p 
MIMAT0000716 
UUUAACAUGGGGGUACC
UGCUG 
miR-496 hsa-miR-496 MIMAT0002818 
UGAGUAUUACAUGGCCA
AUCUC 
miR-135b 
hsa-miR-135b-
5p 
MIMAT0000758 
UAUGGCUUUUCAUUCCU
AUGUGA 
miR-324 hsa-miR-324-3p MIMAT0000762 
ACUGCCCCAGGUGCUGC
UGG 
miR-181d hsa-miR-181d MIMAT0002821 
AACAUUCAUUGUUGUCG
GUGGGU 
miR-1252 hsa-miR-1252 MIMAT0005944 
AGAAGGAAAUUGAAUUC
AUUUA 
miR-93 hsa-miR-93-3p MIMAT0004509 
ACUGCUGAGCUAGCACU
UCCCG 
miR-376c hsa-miR-376c MIMAT0000720 
AACAUAGAGGAAAUUCC
ACGU 
miR-30b* hsa-miR-30b-3p MIMAT0004589 
CUGGGAGGUGGAUGUUU
ACUUC 
miR-616 hsa-miR-616-3p MIMAT0004805 
AGUCAUUGGAGGGUUUG
AGCAG 
miR-664 hsa-miR-664 MIMAT0005949 
UAUUCAUUUAUCCCCAG
CCUACA 
miR-891b hsa-miR-891b MIMAT0004913 
UGCAACUUACCUGAGUC
AUUGA 
miR-448 hsa-miR-448 MIMAT0001532 
UUGCAUAUGUAGGAUGU
CCCAU 
miR-543 hsa-miR-543 MIMAT0004954 
AAACAUUCGCGGUGCAC
UUCUU 
miR-624 hsa-miR-624 MIMAT0004807 
CACAAGGUAUUGGUAUU
ACCU 
miR-624* 
hsa-miR-624-
star 
MIMAT0003293 
UAGUACCAGUACCUUGU
GUUCA 
miR-1234 hsa-miR-1234 MIMAT0005589 
UCGGCCUGACCACCCACC
CCAC 
miR-199a-1 
hsa-miR-199a-
5p 
MIMAT0000231 
CCCAGUGUUCAGACUAC
CUGUUC 
miR-578 hsa-miR-578 MIMAT0003243 
CUUCUUGUGCUCUAGGA
UUGU 
miR-513a-1 
hsa-miR-513a-
3p 
MIMAT0004777 
UAAAUUUCACCUUUCUG
AGAAGG 
miR-603 hsa-miR-603 MIMAT0003271 
CACACACUGCAAUUACU
UUUGC 
miR-1231 hsa-miR-1231 MIMAT0005586 
GUGUCUGGGCGGACAGC
UGC 
miR-183 hsa-miR-183 MIMAT0000261 
UAUGGCACUGGUAGAAU
UCACU 
miR-1827 hsa-miR-1827 MIMAT0006767 UGAGGCAGUAGAUUGAA
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U 
miR-129-2 
hsa-miR-129-2-
3p 
MIMAT0004605 
AAGCCCUUACCCCAAAA
AGCAU 
miR-1246 hsa-miR-1246 MIMAT0005898 
AAUGGAUUUUUGGAGCA
GG 
miR-519e* 
hsa-miR-519e-
5p 
MIMAT0002828 
UUCUCCAAAAGGGAGCA
CUUUC 
miR-1247 hsa-miR-1247 MIMAT0005899 
ACCCGUCCCGUUCGUCCC
CGGA 
miR-365a 
hsa-miR-365a-
3p 
MIMAT0000710 
UAAUGCCCCUAAAAAUC
CUUAU 
miR-503 hsa-miR-503 MIMAT0002874 
UAGCAGCGGGAACAGUU
CUGCAG 
miR-152 hsa-miR-152 MIMAT0000438 
UCAGUGCAUGACAGAAC
UUGG 
miR-10a hsa-miR-10a-5p MIMAT0000253 
UACCCUGUAGAUCCGAA
UUUGUG 
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Appendix 8: Real-Time PCR Data 
 
(A) 4 MiRNA Taqman MiRNA Assay Details 
Assay Name miRBase ID miRBase Accessions AB Assay Target Sequence 
has-miR-378 hsa-miR-378 MIMAT0000732 2243 ACUGGACUUGGAGUCAGAAGG 
hsa-miR-92b hsa-miR-92b MIMAT0003218 007028_mat UAUUGCACUCGUCCCGGCCUCC 
hsa-miR-671-5p hsa-miR-671-5p MIMAT0003880 197646_mat 
AGGAAGCCCUGGAGGGGCUGG
AG 
hsa-miR-1827 hsa-miR-1827 MIMAT0006767 2814 UGAGGCAGUAGAUUGAAU 
 
 
(B) miR-92b of Real-Time PCR Data 
Invasiveness 
miR-
92b Ct 
RNU6 
Ct 
∆Ct  
(miR-92b Ct - RNU6 
Ct) 
∆∆Ct  
(high ∆Ct - low 
∆Ct) 
Fold change (A549-
I7/A549-NI7) 
std dev 
of ∆Ct 
SEM P-value 
high 
rep1 25.07 28.30 -3.23 
  0.392 0.226 
0.014 
rep2 25.12 28.09 -2.97 
rep3 25.24 28.98 -3.74 
mean 25.14 28.46 -3.31 
low 
rep1 25.5 28.14 -2.64 -0.59 1.505 
0.159 0.092 
rep2 25.48 28.09 -2.61 -0.36 1.283 
rep3 25.57 28.64 -3.07 -0.67 1.591 
mean 25.52 28.29 -2.77 -0.54 1.460 
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(C) miR-378 of Real-Time PCR Data 
Invasiveness 
miR-378 
Ct 
RNU6 
Ct 
∆Ct  
(miR-378 Ct - RNU6 
Ct) 
∆∆Ct  
(high ∆Ct - low ∆Ct) 
Fold change 
(A549-I7/A549-
NI7) 
std dev of 
∆Ct 
SEM P-value 
high 
rep1 27.59 28.30 -0.71 
  0.345 0.199 
0.001 
rep2 27.31 28.09 -0.78 
rep3 27.64 28.98 -1.34 
mean 27.51 28.46 -0.94 
low 
rep1 28.27 28.14 0.13 -0.84 1.790 
0.099 0.057 
rep2 28.21 28.09 0.12 -0.90 1.866 
rep3 28.29 28.64 -0.35 -0.99 1.986 
mean 28.26 28.29 -0.03 -0.91 1.881 
 
 
(D) miR-671-5p of Real-Time PCR Data 
Invasiveness 
miR-671-
5p Ct 
RNU6 
Ct 
∆Ct 
(miR-671-5p Ct - RNU6 Ct) 
∆∆Ct  
(high ∆Ct - low ∆Ct) 
Fold change 
(A549-I7/A549-
NI7) 
std dev of 
∆Ct 
SEM P-value 
high 
rep1 31.79 28.30 3.49 
  0.626 0.361 
0.028 
rep2 31.68 28.09 3.59 
rep3 31.44 28.98 2.46 
mean 31.64 28.46 3.18 
low 
rep1 32.06 28.14 3.92 -0.43 1.347 
0.297 0.172 
rep2 32.18 28.09 4.09 -0.50 1.414 
rep3 32.02 28.64 3.38 -0.92 1.892 
mean 32.09 28.29 3.80 -0.62 1.551 
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(E) miR-1827 of Real-Time PCR Data 
Invasiveness 
miR-1827 
Ct 
RNU6 
Ct 
∆Ct = (miR-1827 Ct - 
RNU6 Ct) 
∆∆Ct = (high ∆Ct - 
low ∆Ct) 
Fold change 
(A549-I7/A549-
NI7) 
std dev of 
∆Ct 
SEM P-value 
high 
rep1 35.75 28.30 7.45 
  0.727 0.420 
0.012 
rep2 36.96 28.09 8.87 
rep3 36.87 28.98 7.89 
mean 36.53 28.46 8.07 
low 
rep1 33.74 28.14 5.6 1.85 0.277 
0.095 0.055 
rep2 33.83 28.09 5.74 3.13 0.114 
rep3 33.35 28.64 4.71 3.18 0.110 
mean 33.64 28.29 5.35 2.72 0.167 
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Appendix 9: Target Prediction Data 
 
(A) Putative Gene Targets of miRNAs using TargetScan 5.2 Algorithm 
Target gene 
Total context score (≤ 0.10) 
miR-378 
miR-671-
5p 
miR-25* 
†
 miR-92b 
miR-
106b* 
†
 
miR-550* 
†
 
miR-629* 
†
 
miR-576-
3p 
miR-886-
5p 
miR-487b miR-1827 
TGFB1 - - N/A - N/A N/A N/A - - - -0.14 
TGFB3 - - N/A - N/A N/A N/A -0.14 - - - 
TGFBR2 - - N/A - N/A N/A N/A - - - -0.34 
SMAD2 - - N/A -0.17 N/A N/A N/A - - -0.38 -0.31 
SMAD3 - -0.26 N/A - N/A N/A N/A - - - -0.12 
SMAD7 - -0.11 N/A -0.34 N/A N/A N/A - - - - 
SMURF1 - - N/A -0.16 N/A N/A N/A - - - -0.17 
CDH1 - -0.23 N/A -0.10 N/A N/A N/A - - - - 
WNT5A - - N/A - N/A N/A N/A -0.27 - - -0.20 
FZD3 - -0.27 N/A - N/A N/A N/A - - - - 
VANGL1 -0.37 - N/A -0.59 N/A N/A N/A -0.33 - - -0.10 
DVL3 - -0.56 N/A - N/A N/A N/A - - - -0.25 
SFRP4 - - N/A - N/A N/A N/A -0.22 - - -0.25 
PRICKLE2 - - N/A -0.12 N/A N/A N/A - - - - 
PRICKLE4 - -0.27 N/A - N/A N/A N/A - - - - 
ITGB3 - - N/A - N/A N/A N/A - - - -0.12 
ITGB8 - - N/A - N/A N/A N/A - - - -0.41 
ARHGEF7 - - N/A - N/A N/A N/A - - - -0.11 
PAK1 - - N/A - N/A N/A N/A - - - -0.22 
PAK6 - -0.21 N/A - N/A N/A N/A - - - -0.17 
PAK7 - - N/A - N/A N/A N/A - - -0.44 - 
CDC42 - - N/A -0.16 N/A N/A N/A - - - -0.18 
WASF2 - -0.10 N/A - N/A N/A N/A - - - -0.36 
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WASF3 - - N/A - N/A N/A N/A -0.23 - - - 
ARPC5 - - N/A - N/A N/A N/A - - - -0.17 
LIMK1 - - N/A - N/A N/A N/A - - - -0.11 
GRB2 -0.17 -0.21 N/A - N/A N/A N/A - - - -0.35 
HIF1A - - N/A - N/A N/A N/A -0.24 - - - 
SUFU -0.14 - N/A - N/A N/A N/A - - - -0.22 
†
TargetScan 5.2 algorithm do not predicts miRNA* (miR-25*, miR-106b*, miR-550* and miR-629*). 
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(B) Putative Gene Targets of miRNAs using DIANA-microT 4.0 algorithm 
Target gene 
miTG score (≥ 0.10) 
miR-378 
miR-671-
5p 
miR-25* miR-92b 
miR-
106b* 
miR-550* miR-629* 
miR-576-
3p 
miR-886-
5p 
miR-487b miR-1827 
TGFB3 - - - - - 0.212 0.291 - - - - 
TGFBR2 - 0.377 - - - - - 0.214 - - 0.445 
SMAD2 - - - - - 0.217 0.230 - - - 0.365 
SMAD3 - 0.409 - - - - - - - - - 
SMAD7 - 0.431 - - - - - - - - - 
SMURF2 - - - - - 0.218 - - - - - 
CDH1 0.220 - - 0.224 - - - - - - - 
WNT5A 0.287 0.206 - 0.415 - - - 0.381 - - - 
FZD3 - - - - - - 0.226 0.248 - - - 
VANGL1 0.416 - - - - 0.208 0.362 0.292 - - - 
DVL3 - 0.493 - - - - - - - - 0.311 
DAAM1 - - - 0.472 - - 0.205 0.539 - - - 
SFRP4 - 0.238 - - - - - 0.419 - - - 
PRICKLE2 - 0.244 - 0.203 - 0.216 0.284 0.203 - - - 
ITGA3 - - - - - - - - 0.233 - - 
ITGA6 - - - - - - - - - 0.471 - 
ITGB3 - - - 0.348 - - - - - - - 
ITGB8 - 0.225 - 0.235 - 0.214 0.235 - - - 0.378 
PAK1 - 0.316 - - - - 0.386 - - - 0.430 
PAK6 - - - - - - - 0.231 - - 0.419 
PAK7 - - - - - - 0.326 0.215 - 0.429 - 
CDC42 - - - - - - 0.362 - - - 0.324 
WASF3 - 0.212 - - - - - 0.224 - - - 
LIMK1 - - - - - - - - - - 0.326 
GRB2 0.414 0.338 - - - - - - - - - 
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MAPK14 - - - - - - 0.579 - - - - 
MAPK13 - - - - - - 0.346 - - - - 
PIK3R5 - - - - - - 0.334 - - - - 
PIK3R2 - - - - - - - - 0.247 - - 
PIK3C2A - - - - - - - - - 0.332 - 
HIF1A - - - - - - - 0.434 - - - 
 
 
